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A B S T R A C T
Background
Specific treatments for influenza are limited to neuraminidase inhibitors and adamantanes. Corticosteroids show evidence of benefit
in sepsis and related conditions, most likely due to their anti-inflammatory and immunomodulatory properties. Although commonly
prescribed for severe influenza, there is uncertainty over their potential benefit or harm.
Objectives
To systematically assess the effectiveness and potential adverse effects of corticosteroids as adjunctive therapy in the treatment of
influenza, taking into account differences in timing and doses of corticosteroids.
Search methods
We searched CENTRAL (2015, Issue 5), MEDLINE (1946 to June week 1, 2015), EMBASE (1974 to June 2015), CINAHL (1981 to
June 2015), LILACS (1982 to June 2015), Web of Science (1985 to June 2015), abstracts from the last three years of major infectious
disease and microbiology conferences, and references of included articles.
Selection criteria
We included randomised controlled trials (RCTs), quasi-RCTs and observational studies that compared corticosteroid treatment with
no corticosteroid treatment for influenza or influenza-like illness. We did not restrict studies by language of publication, influenza
subtypes, clinical setting or age of participants. We selected eligible studies in two stages: sequential examination of title and abstract,
followed by full text.
Data collection and analysis
Two pairs of review authors independently extracted data and assessed risk of bias. We pooled estimates of effect using random-effects
meta-analysis models, where appropriate. We assessed heterogeneity using the I2 statistic and assessed the quality of the evidence using
the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.
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Main results
We identified 19 eligible studies (3459 individuals), all observational; 13 studies (1917 individuals) were suitable for inclusion in the
meta-analysis of mortality. Of these, 12 studied patients infected with 2009 influenza A H1N1 virus (H1N1pdm09). Risk of bias
was greatest in the ’comparability domain’ of the Newcastle-Ottawa scale, consistent with potential confounding by indication. Data
specific to mortality were of very low quality. Reported doses of corticosteroids used were high and indications for their use were not
well reported. Onmeta-analysis, corticosteroid therapy was associated with increased mortality (odds ratio (OR) 3.06, 95% confidence
interval (CI) 1.58 to 5.92). Pooled subgroup analysis of adjusted estimates of mortality from four studies found a similar association
(OR 2.82, 95% CI 1.61 to 4.92). Three studies reported greater odds of hospital-acquired infection related to corticosteroid therapy;
all were unadjusted estimates and we graded the data as very low quality.
Authors’ conclusions
We did not identify any completed RCTs of adjunctive corticosteroid therapy for treating influenza. The available evidence from
observational studies is of very lowquality with confounding by indication amajor potential concern. Althoughwe found that adjunctive
corticosteroid therapy was associated with increased mortality, this result should be interpreted with caution. In the context of clinical
trials of adjunctive corticosteroid therapy in sepsis and pneumonia that report improved outcomes, including decreased mortality, more
high-quality research is needed (both RCTs and observational studies). Currently, we do not have sufficient evidence in this review to
determine the effectiveness of corticosteroids for patients with influenza.
P L A I N L A N G U A G E S U M M A R Y
Steroids for the treatment of influenza
Review question
We reviewed the evidence regarding the effect of additional (’adjunctive’) steroid treatment in individuals with influenza infection.
Background
The majority of individuals with influenza have a fever, headache and a cough and get better without any specific treatment. However,
a small proportion of people develop a more severe form of influenza, requiring admission to an intensive care unit in hospital. These
patients are often prescribed steroids as part of their treatment, although the evidence that steroids are beneficial in these circumstances
is controversial.
Study characteristics
We searched for studies comparing additional steroid treatment with no additional steroid treatment in individuals with influenza.
This evidence is current to June 2015. We identified a total of 19 studies with 3459 individuals; none of them were clinical trials. The
majority of studies investigated adults admitted to hospital with pandemic influenza in 2009 and 2010.
Key results
We did not find any relevant clinical trials on this topic. The evidence available from existing observational studies was of very low
quality.We found that patients with influenza who received additional steroid treatmentmight have had a greater risk of death compared
to patients who did not receive steroid treatment. Hospital-acquired infection was the main ’side effect’ related to steroid treatment that
was reported in the included studies; all studies reported a greater risk of hospital-acquired infection in the group treated with steroids.
However, it was not possible to be certain if patients with more severe influenza were selected to receive steroid treatment in the first
place. Therefore, it is not possible to be certain whether additional steroid treatment in patients with influenza is truly harmful, or not.
Clinical trials of additional steroids in the treatment of individuals with influenza are therefore warranted to clarify the situation. In
the meantime, the use of steroids in influenza remains a clinical judgement call.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Effect of corticosteroid therapy on influenza- related outcomes
Patient or population: individuals with inf luenza
Settings: in-hospital
Intervention: cort icosteroid therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Corticosteroid therapy
M ortality 141 per 1000 334 per 1000
(206 to 493)
OR 3.06
(1.58 to 5.92)
1915
(13 studies)
⊕©©©
very lowa
Hospital- acquired infec-
tion
See comment See comment Not est imable 619
(3 studies)
⊕©©©
very lowb
Critical illness (composite
outcome including death
and intensive care unit ad-
mission)
See comment See comment Not est imable 322
(2 studies)
⊕©©©
very lowc
M echanical ventilation See comment See comment Not est imable 377
(2 studies)
⊕©©©
very lowd
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.3
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aPooled analysis. We downgraded the quality of evidence f rom low (observat ional data) to very low due to high risk of
indicat ion bias (sicker adults with inf luenza were more likely to receive cort icosteroids) and clinical/ stat ist ical heterogeneity
(unadjusted est imates of odds rat io for mortality were presented in some studies and the def init ion of mortality varied
across the studies). We upgraded the quality of evidence once as plausible confounding was likely to change the ef fect
est imate.
bResults were not pooled. We downgraded the quality of evidence f rom low (observat ional data) to very low due to high
risk of indicat ion bias (sicker adults with inf luenza were more likely to receive cort icosteroids) and clinical and stat ist ical
heterogeneity (unadjusted est imates of odds rat io for hospital-acquired infect ion were presented in all studies, and the
def init ions for hospital-acquired infect ion varied across the studies). We upgraded the quality of evidence once as plausible
confounding was likely to change the ef fect est imate.
cResults were not pooled. We downgraded the quality of evidence f rom low (observat ional data) to very low due to high
risk of indicat ion bias (sicker adults with inf luenza were more likely to receive cort icosteroids) and clinical and stat ist ical
heterogeneity (unadjusted est imates of odds rat io and risk rat io for crit ical illness were presented in all studies, and the
def init ions for crit ical illness varied across the studies). We upgraded the quality of evidence once as plausible confounding
was likely to change the ef fect est imate.
dResults were not pooled. We downgraded the quality of evidence f rom low (observat ional data) to very low due to high
risk of indicat ion bias (sicker adults with inf luenza were more likely to receive cort icosteroids) and clinical and stat ist ical
heterogeneity (unadjusted est imates of odds rat io for mechanical vent ilat ion were presented in all studies). We upgraded the
quality of evidence once as plausible confounding was likely to change the ef fect est imate.
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B A C K G R O U N D
Description of the condition
Influenza is a significant cause of morbidity and mortality world-
wide and has a high financial burden. Seasonal influenza occurs
annually during the winter months in temperate zones of both
the Northern and Southern hemispheres and all year round in
the tropics (Viboud 2006). Global estimates of seasonal influenza
from the World Health Organization (WHO) report one billion
cases, including three to five million cases of severe illness annually
(WHO2008). About 210,000 influenza-related respiratory deaths
occur globally per influenza season; 81% of these in persons aged
65 years and above (Simonsen 2013). The reported per capita total
cost of a case of influenza illness in national studies ranges from
USD 27 to USD 52 in European countries and USD 45 to USD
63 in the United States (Peasah 2013). Estimates of the influenza-
related hospitalisation rate in the United States range from 63 to
107 per 100,000 persons annually at a cost of USD 11,096 to
USD 83,216 per admission; amongst adults, hospitalisation rates
are highest in persons aged 65 years age and above (309/100,000)
(Peasah 2013; Zhou 2012). The population-based incidence esti-
mate for influenza-associated critical illness in the USA is 12 per
100,000 person-years; this represents 1.3% of all critical illness
hospitalisations or 3.4% of critical illness hospitalisations during
the influenza season (Ortiz 2014a). Estimates from the United
Kingdom indicate an influenza-attributable annual GP consulta-
tion rate of 2156 per 100,000 population and a corresponding
annual hospitalisation rate of 34 per 100,000 population (Cromer
2014).
Pandemic influenza occurs unpredictably and infrequently due
to reassortment of the influenza virus or adaptive mutation of a
virus that has crossed the species barrier (Taubenberger 2008). Al-
though the case fatality ratio associated with the recent influenza
A (H1N1) pandemic in 2009 and 2010 was lower in comparison
to previous pandemics (0.03% versus 2.5% in 1918 and 1919)
(Donaldson 2010), a modelling study of global mortality due to
the recent pandemic estimated 201,200 respiratory deaths and
83,300 cardiovascular deaths, with 80% of the deaths in individ-
uals younger than 65 years (Dawood 2012). This shift in mor-
tality towards younger age groups was estimated to have led to
between 334,000 and 1,973,000 ’years of life lost’ in the United
States alone (Viboud 2010). Worldwide clinical data from the in-
fluenza A (H1N1) pandemic in 2009 revealed that more than
one-fifth of hospitalised individuals experienced severe disease re-
quiring admission to an intensive care unit (Jain 2009; Muthuri
2013; Richard 2012). The onset of critical illness following hos-
pital admission occurred rapidly (median one day) and was com-
monly due to acute respiratory distress syndrome with refractory
hypoxaemia, septic shock and/or multisystem organ failure, often
requiring prolonged ventilation (Jain 2009; Kumar 2009). Criti-
cal care delivery systems were overwhelmed, especially in low and
middle-income countries, affecting entire hospital services down-
stream (Ortiz 2013). The mortality associated with critical care
admission due to severe influenza was high (14% to 22%) (Jain
2009; Richard 2012).
Current antiviral treatment options for influenza are limited to
the neuraminidase inhibitors (NI) and adamantanes, although
widespread adamantane use has been hampered by the global
emergence of drug resistance (Deyde 2007). A Cochrane system-
atic review of randomised placebo-controlled trials (RCTs) re-
ported a reduced time to first alleviation of symptoms by 0.6 to 0.7
days in NI treated adults, but no differences were seen between the
two groups with regard to hospitalisation rates or occurrence of
influenza-related adverse events (Jefferson 2014). In contrast, an
individual patient level meta-analysis of over 29,000 patients with
2009 influenza A H1N1 virus (H1N1pdm09) infection from 78
observational studies across the world found that NI treatment
at any time, in comparison to no treatment, was associated with
a 19% reduction in mortality risk; early treatment (within two
days of symptom onset) was associated with a 52% reduction in
mortality risk in comparison to late treatment (Muthuri 2013).
Description of the intervention
Endogenous corticosteroids are produced principally in the
adrenal glands from cholesterol and are regulated by the hypotha-
lamic-pituitary-adrenal (HPA) axis (Molenaar 2012); they pos-
sess several anti-inflammatory, immunomodulatory and vascular
properties including inhibition of pro-inflammatory cytokines, re-
duction of leucocyte trafficking, stimulation of apoptosis of T-
lymphocytes, maintaining endothelial integrity and vascular per-
meability and regulation of vascular tone by inhibition of va-
sodilators (nitrous oxide) and increasing sensitivity to vasopressors
(Coutinho 2011; Kaufmann 2007; Rhen 2005). These properties
form the rationale for testing corticosteroids in sepsis and related
conditions.
A systematic review of RCTs investigating sepsis and septic shock
reported that low-dose corticosteroid use increased 28-day shock
reversal and reduced intensive care unit length of stay and 28-day
mortality (Annane 2009). For the treatment of bacterial meningi-
tis, corticosteroids appear to reduce hearing loss and neurological
complications (Brouwer 2010), while in tuberculous meningitis,
an improvement in survival was reported (Prasad 2008).
With regard to respiratory infections, a Cochrane systematic re-
view of systemic corticosteroid use in all-cause pneumonia found
no overall mortality benefit, but a reduction in time to resolution
of symptoms was seen; in a subgroup of individuals with severe
pneumonia, a reduction in the need formechanical ventilation and
improved oxygenation was found (Chen 2011). A further meta-
analysis that included additional RCTs reported a survival benefit
from corticosteroid therapy in the subgroup of severe pneumo-
nia (Nie 2012). A RCT in 2015 found a lower risk of treatment
failure with adjunctive corticosteroid therapy in hospitalised pa-
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tients with severe community-acquired pneumonia with a high
inflammatory response (Torres 2015), while a RCT in hospitalised
patients with community-acquired pneumonia found adjunctive
corticosteroids were associated with a reduction in the time to
clinical stability (Blum 2015). The most recent meta-analysis, in-
cluding the latest studies, suggests an overall beneficial effect from
adjunctive corticosteroids in the treatment of patients with com-
munity-acquired pneumonia (Siemieniuk 2015). There is limited
evidence that systemic corticosteroids as adjunctive therapy to an-
tibiotics in people with acute sinusitis may offer modest benefits
for short-term symptom relief (Venekamp 2014). In children with
croup, a review found that corticosteroid treatment was associated
with a lower symptom score at six hours, re-admission rate and
length of stay (Russell 2011). In infants and young children with
acute viral bronchiolitis, no benefits were seen in hospital admis-
sion rates, or length of stay in hospital following systemic or in-
haled corticosteroid use (Fernandes 2013).
The role of corticosteroids for the treatment of influenza is
highly controversial. While some case series have reported im-
proved outcomes with corticosteroid treatment of severe influenza
(Quispe-Laime 2010), other cohort studies have suggested the op-
posite (Diaz 2012; Liem 2009). Despite the ongoing controversy,
9% of hospitalised individuals and up to 69% of critically ill indi-
viduals during the 2009 influenza A (H1N1) pandemic were pre-
scribed corticosteroid therapy (Brun-Buisson 2011; Diaz 2012;
Kumar 2009;Muthuri 2013). TheWHO consultation on human
influenza A (H5N1) infection reported that 47% to 70% of pa-
tients received corticosteroids during the 2004 to 2005 outbreak
in South East Asia (WHO 2005).
How the intervention might work
Viral replication and production of cytokines through activation
of the host innate immune system are central to the pathogenesis of
influenza infection (de Jong 2006). Elevated or excessive produc-
tion of cytokines (hypercytokinaemia) correlates with symptoms
and fever in acute influenza (Kaiser 2001). Comparisons between
patients with mild and severe pandemic influenza have revealed
significantly higher levels of cytokines (especially interleukin-6) in
the plasma of patients with severe disease (Yu 2011) and similar
findings have been replicated in studies of severe seasonal influenza
(Heltzer 2009). A combination of excessive pro-inflammatory cy-
tokine induced inhibition of the HPA axis, substrate (cholesterol)
deficiency, structural damage to the adrenal gland due to infarc-
tion of haemorrhage and peripheral corticosteroid resistance could
lead to absolute or relative corticosteroid insufficiency during crit-
ical illness (Jaattela 1991; Liu 2002; Marik 2009). The overall in-
cidence of adrenal insufficiency in patients with critical illness is
estimated to be around 20% and up to 60% in those with sepsis
and septic shock (Marik 2009). Administration of corticosteroids
during critical illness, including severe influenza, may attenuate
this state of adrenal insufficiency and help maintain homeostasis.
Why it is important to do this review
Treatment options for influenza are limited. Corticosteroids may
offer an additional therapeutic option and although they are fre-
quently prescribed for severely ill individuals with influenza, there
is controversy regarding the benefits and harms. A systematic re-
view of the current evidence would a) highlight the quality of the
available evidence and b) valuably inform current clinical practice
and future research needs.
O B J E C T I V E S
To systematically assess the effectiveness and potential adverse ef-
fects of corticosteroids as adjunctive therapy in the treatment of
influenza, taking into account differences in timing and doses of
corticosteroids.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), quasi-experimental designs
and observational cohort studies of individuals with influenza in-
vestigating corticosteroid treatment versus no corticosteroid ther-
apy were considered for inclusion. We excluded studies with case-
control designs due to the inability to determine temporal effects
of corticosteroids on the development of non-mortality outcomes.
We excluded studies with fewer than 10 participants.
Types of participants
Individuals with:
1. clinically diagnosed influenza or influenza-like illness
(defined as fever, cough, symptoms of upper respiratory tract
infection (coryza, sore throat) and constitutional symptoms
(headache, myalgia) of acute onset); and/or
2. microbiologically confirmed influenza through sampling of
the respiratory tract (nasal swabs, throat swabs or
bronchoalveolar lavage).
There were no restrictions on age, influenza subtypes or study
setting.
Types of interventions
We considered studies investigating corticosteroid treatment ver-
sus no corticosteroid treatment for inclusion. There were no re-
strictions on the doses of corticosteroid nor the types of corticos-
teroid used. We considered corticosteroid administration by oral
and intravenous routes.
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Types of outcome measures
Primary outcomes
1. For studies of hospitalised patients:
i) number of deaths at 30 days following admission (30-
day mortality);
ii) rate of admission to intensive care units.
2. For studies in the community setting:
i) rate of hospitalisation;
ii) time to resolution of symptoms;
iii) 30-day mortality.
When studies reported mortality as an outcome following adjust-
ment for potential confounders such as disease severity and pa-
tient demographics among other variables, this is referred to as
’adjusted mortality’.
Secondary outcomes
1. For studies of hospitalised patients:
i) hospital re-admission rate at 30 days post-discharge;
ii) number and nature of adverse events secondary to
corticosteroid use, such as incidence of gastrointestinal bleeding,
hospital-acquired infections and metabolic complications (e.g.
hyperglycaemia, hypernatraemia);
iii) proportion of patients requiring mechanical
ventilation;
iv) length of stay in hospital.
2. For studies in the community setting:
i) number and nature of adverse events secondary to
corticosteroid use, such as incidence of gastrointestinal bleeding,
hospital-acquired infections and metabolic complications (e.g.
hyperglycaemia, hypernatraemia).
Search methods for identification of studies
Electronic searches
We searched the following electronic databases: Cochrane Central
Register of Controlled Trials (CENTRAL 2015, Issue 5), which
contains the Cochrane Acute Respiratory Infections Group’s Spe-
cialised Register, MEDLINE (1946 to June week 1, 2015), EM-
BASE (1980 to June 2015), CINAHL (1981 to June 2015),
LILACS (1982 to June 2015) and Web of Science (1985 to June
2015).
The search strategy implemented in CENTRAL and MEDLINE
is listed below. We used the Cochrane Highly Sensitive Search
Strategy for identifying randomised trials for the initial search in
the MEDLINE database (Lefebvre 2011). We then repeated the
MEDLINE search, replacing the randomised trial filter with the
Scottish Intercollegiate Guidelines Network (SIGN) filter to iden-
tify observational studies (SIGN 2011). We combined these two
searches to give the search results forMEDLINE.We repeated this
process to searchEMBASE (Appendix 1),CINAHL(Appendix 2),
LILACS (Appendix 3) andWeb of Science (Appendix 4), adapting
the filter as needed.
MEDLINE (Ovid)
1 Influenza, Human/
2 exp Influenzavirus A/
3 exp Influenzavirus B/
4 (influenza* or flu).tw.
5 (h1n1 or h5n1 or h3n2).tw.
6 or/1-5
7 exp Adrenal Cortex Hormones/
8 corticosteroid*.tw,nm.
9 adrenal cortex hormon*.tw.
10 (adren* cortic* adj1 (hormone* or steroid*)).tw.
11 adrenocorticosteroid*.tw,nm.
12 adrenocorticoid*.tw,nm.
13 corticoid*.tw,nm.
14 glucocorticoid*.tw,nm.
15 hydroxycorticosteroid*.tw,nm.
16 exp Steroids/
17 steroid*.tw,nm.
18 (hydrocortisone* or prednisolone* or prednisone* or dexam-
ethasone* or methylprednisolone*).tw,nm.
19 or/7-18
20 6 and 19
There will be no date, publication or language restrictions.
Searching other resources
We searched the Controlled Trials Registry for ongoing clinical
trials (www.controlled-trials.com). We scrutinised the bibliogra-
phies of included studies and the last three years of three major
infectious diseases conferences (Interscience Conference on An-
timicrobial Agents and Chemotherapy (ICAAC), European Soci-
ety of Clinical Microbiology and Infectious Diseases (ESCMID)
and Asia Pacific Society of Infection Control (APSIC)) to iden-
tify potentially eligible studies. Following execution of the search
strategy, we individually contacted four domain experts to ensure
relevant studies had been identified (see Acknowledgements).
Data collection and analysis
Selection of studies
Two review authors (CR, WSL) independently reviewed all the
citations retrieved using the search strategy described above. We
selected studies in two stages: analysis of study titles and abstracts
in the first stage, followed by analysis of the full text of the articles.
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A third review author (JVT) resolved disagreements at any of these
stages through discussion.
Data extraction and management
Two review authors independently extracted data (CR extracted
data from all eligible studies independently; JLB, JVT and WSL
shared the data extraction of all included studies) using a standard-
ised proforma that was previously piloted and specifically adapted
for this review. We obtained the following data from studies:
1. characteristics of study (design, setting, country, enrolment
period, methodological details including ’risk of bias’ criteria for
RCTs and the Newcastle-Ottawa Scale for non-randomised trials
and comparative observational studies);
2. characteristics of participants (inclusion and exclusion
criteria, demographics, co-morbid illnesses, disease severity,
numbers in each group);
3. characteristics of intervention (type of steroid, route of
administration, dose, timing of corticosteroid use (early versus
late) and duration of treatment, co-interventions administered);
4. outcome measures.
Assessment of risk of bias in included studies
Twoauthors (CR, JLB) independently assessed themethodological
quality of experimental studies using the Cochrane ’Risk of bias’
tool in the following domains (Higgins 2011):
1. adequacy of the method for generating the randomisation
sequence;
2. adequacy of the method for allocation concealment;
3. blinding of participants, clinicians and outcome assessors
with regards to the intervention given;
4. incomplete outcome data (participants lost to follow-up in
each treatment group and reasons for losses reported);
5. analysis of participants in the groups to which they were
originally randomised (intention to treat (ITT) principle);
6. selective outcome reporting (all primary outcomes listed in
the study protocol that are relevant to this review reported);
7. other potential sources of bias.
We used the validated ’star system’ of the Newcastle-Ottawa Scale
to assess the risk of bias at the outcome level in observational
studies in the following three domains (Newcastle-Ottawa Scale
2014):
1. selection of study groups;
2. comparability of groups;
3. ascertainment of outcome.
Measures of treatment effect
We extracted dichotomous outcome data from individual studies
as tabulated data from which risk ratios (RR) or odds ratios (OR)
and 95% confidence intervals (CI) were estimated. We extracted
adjusted outcome measures as ORs or hazard ratios (HRs) with
95% confidence intervals (CIs) and presented these separately in
pooled analyses. For normally distributed continuous data, we cal-
culated mean difference or standardised mean difference with cor-
responding 95% CIs. We used medians and inter-quartile ranges
for continuous data that were not normally distributed.
Unit of analysis issues
We considered the individual participant to be the unit of analysis
for RCTs. We analysed cluster-RCTs allowing for that level of
randomisation.
Dealing with missing data
We analysed data on an ITT basis. For dichotomous outcomes,
we assessed the effect assuming participants with missing data
had a poor outcome. We did not use any form of imputation for
participants withmissing continuous outcome data.We consulted
the CONSORT-type flow chart of participants through the study
if available (Schulz 2010). If a flow chart was not available, we
looked for information in the text of the results to determine
whether all participants included in the study had been analysed.
In case of ambiguity, we contacted the trial authors to seek further
information.
In the case ofmissing data relating to results, for example,measures
of dispersion, we contacted the trial authors of the study to request
further information.
Assessment of heterogeneity
We used the I2 statistic to assess heterogeneity across experimental
and observational studies. We considered a value greater than 50%
to reflect substantial heterogeneity between the findings of RCTs
(as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011)). However, for observational studies,
due to the inherent biases within their design, we considered a
value greater than 75% to reflect substantial heterogeneity.
Assessment of reporting biases
We assessed funnel plots for publication bias (small study bias).
Data synthesis
One review author (CR) entered data into Review Manager
(RevMan 2014), and two review authors (CR, JLB) independently
summarised the data. In the case of experimental studies, where
the interventions and populations were similar, we used a random-
effects meta-analysis to pool data due to the potential for inherent
biases in the studies. We elected only to use the random-effects
model to pool data due to the likely differences in the effective-
ness of corticosteroids by patient characteristics. We did not use a
fixed-effect model to analyse the data because a) there was a clear
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rationale for choosing the random-effects model, and b) there was
no concern about the influence of small study effects.
For observational studies, we extracted tabulated data, crude es-
timates and adjusted estimates of effect from the studies. We ex-
tracted adjusted outcome measures as ORs or HRs with 95% CIs
and presented separately in pooled analyses. We used a similar
meta-analysis method to pool data from observational studies as
described for the RCTs. Where data were available, we presented
subgroup analyses of adjusted or unadjusted estimates separately
(if both types of data were available, we used adjusted estimates of
effect in preference to minimise potential confounding between
the treatment groups).
GRADE and ’Summary of findings’ table
We created a ’Summary of findings’ table for the outcomes of mor-
tality, adverse events, rates of mechanical ventilation and critical
disease (composite outcome including death and intensive care
unit admission). We used the five GRADE considerations (study
limitations, consistency of effect, imprecision, indirectness and
publication bias) to assess the quality of a body of evidence as
it relates to the studies that contribute data to the meta-analyses
for the prespecified outcomes (Atkins 2004). We used the meth-
ods and recommendations described in Section 8.5 and Chapter
12 of the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011), and we used GRADEpro GDT software
(GRADEproGDT 2015).We justified all decisions to downgrade
or upgrade the quality of studies using footnotes, and we made
comments to aid the reader’s understanding of the review where
necessary.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analyses in the following areas if possible:
1. daily corticosteroid dose (low versus high; in adults low-
dose is defined as hydrocortisone ≤ 300 mg, dexamethasone ≤
12 mg, prednisolone ≤ 75 mg, methylprednisolone ≤ 60 mg)
(Annane 2004);
2. timing of corticosteroid use (early versus late; early defined
as < four days of onset of symptoms and late ≥ four days)
(Annane 2002; Jain 2009; Nguyen-Van-Tam 2010);
3. duration of corticosteroid course (short versus long course,
short course defined as < five days and long course ≥ five days)
(Annane 2004);
4. adult versus child population (adult defined as ≥ 16 years);
5. route of administration (intravenous, oral);
6. seasonal influenza versus pandemic/outbreak influenza.
Sensitivity analysis
We performed sensitivity analyses to assess the effect of study de-
sign on the primary and secondary outcomes using stratification
if a sufficient number of studies were present.
R E S U L T S
Description of studies
Results of the search
The search strategy identified 3416 articles, of which we assessed
2812 articles in first stage of the selection process after removal
of duplicate articles (Figure 1). We scrutinised the full text of 95
potentially eligible articles, yielding 19 articles for inclusion in the
systematic review. The main reason for exclusion of 76 articles was
the lack of data comparing corticosteroid use versus no corticos-
teroid use; 10 of these studies that came closest to being included
in the review and their respective reasons for exclusion have been
summarised in the Characteristics of excluded studies table. Of
articles included in the systematic review, 13 were included in the
meta-analysis of mortality (Balaganesakumar 2013; Brun-Buisson
2011; Chawla 2013; Diaz 2012; Kim 2011; Li 2012; Liem 2009;
Linko 2011; Mady 2012; Patel 2013; Sertogullarindan 2011;
Viasus 2011; Xi 2010). We included the remaining six articles
in the narrative synthesis only, as three studies investigated corti-
costeroid therapy prior to the diagnosis of influenza (Boudreault
2011; Delgado-Rodriguez 2012; Wu 2012). Three reported out-
comes other than mortality according to corticosteroid use (Han
2011; Jain 2009; Kudo 2012).
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Figure 1. Study flow diagram.
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Included studies
The study design, participant, intervention and outcome charac-
teristics of the included studies are summarised in Table 1. All were
observational designs. Outcome data according to corticosteroid
use were reported for a total of 3459 individuals. All studies were
conducted, at least in part, within a hospital setting: seven studies
consisted only of individuals admitted to the intensive care unit
(ICU) (n = 1140); 10 studies investigated admissions to both ICUs
and hospital wards (n = 1970); one study included individuals
from non-ICU wards only (n = 143); and one study investigated
both out-patients and in-patients (n = 206). The viral aetiology
of individuals included in the studies was as follows: 13 studies
of 2009 influenza A H1N1 virus (H1N1pdm09) (n = 3072); two
studies of seasonal influenza (n = 349); and one study of influenza
A (H5N1) (n = 38).
The median age of the cohort or corticosteroid treatment groups
was reported in 13 studies (varying from 8 to 51 years). Of seven
studies reporting disease severity according to corticosteroid treat-
ment, adults receiving corticosteroid therapy had higher disease
severity scores in comparison to their respective comparator groups
in three studies (n = 543) (Kim 2011; Linko 2011; Viasus 2011),
while the remaining four studies reported no difference in dis-
ease severity scores between the two groups (n = 749) (Table 1)
(Brun-Buisson 2011; Diaz 2012; Han 2011; Mady 2012).
In all studies, comparisons were made between patients treated
with or without corticosteroids in addition to supportive treat-
ment, including antiviral agents. Eight studies reported the doses
or regimens of corticosteroid administered; in four studies, the
mean/median dose of corticosteroid therapy varied between 67.5
mg to 117.5 mg of prednisolone equivalent per day (Brun-Buisson
2011; Kim 2011; Linko 2011; Xi 2010), and four studies reported
daily regimens of methylprednisolone 1 mg to 6mg per kg (equiv-
alent to 1.25 mg to 7.5 mg prednisolone per kg) (Table 1) (Kudo
2012; Liem 2009; Mady 2012; Patel 2013). The median duration
of corticosteroid therapy was reported in four studies and varied
from 5.1 to 11.0 days.
Risk of bias in included studies
As all identified studies were observational, we used theNewcastle-
Ottawa Scale to assess risk of bias throughout this review. The risk
of bias for 27 reported outcomes from 19 studies included in this
review is summarised in Table 2. We awarded a maximum score
of four stars for the ’selection’ domain to the following studies and
their respective outcomes: Jain 2009 (ICU admission/death ver-
sus survival/no ICU admission); Kim 2011 (mortality, mechan-
ical ventilation, length of stay and hospital-acquired infection);
Kudo 2012 (length of stay); Liem 2009 (in-hospital mortality);
Linko 2011 (in-hospital mortality, length of stay, mechanical ven-
tilation); Viasus 2011 (in-hospital mortality, hospital-acquired in-
fection) and Wu 2012 (influenza requiring hospitalisation). We
gave the lowest score of two stars for the ’selection’ domain to the
following studies: Balaganesakumar 2013 (mortality); Boudreault
2011 (time to death); Li 2012 (mortality) and Patel 2013 (mor-
tality).
The ’comparability’ domain performed the poorest across all the
studies in the risk of bias assessment. We awarded a maximum of
two stars to the following studies and their respective outcomes:
Brun-Buisson 2011 (in-hospital mortality); Delgado-Rodriguez
2012 (composite outcome of ICU admission and mortality); Diaz
2012 (ICU mortality); Han 2011 (critical illness); Kim 2011
(mortality) and Linko 2011 (in-hospital mortality). The majority
of the remainder of the studies failed to score any stars for this
domain.
The ’outcome’ domain performed the best across all studies, with
15 of the 19 studies achieving a maximum score of three stars
across all assessed outcomes; the remainder of the four studies
achieved two stars: Balaganesakumar 2013 (mortality); Boudreault
2011 (time to death); Diaz 2012 (ICUmortality); and Kudo 2012
(length of stay).
Effects of interventions
See: Summary of findings for the main comparison Effect of
corticosteroid therapy on influenza-related outcomes
The 15 studies of 2009 influenza A H1N1 virus (H1N1pdm09)
reported no difference in or greater adverse outcomes associated
with corticosteroid use. The single study of influenza A/H5N1
found that corticosteroid therapy was associated with increased
mortality following adjustment for neutropenia as a marker of
disease severity (Liem 2009). Two studies of individuals with sea-
sonal influenza failed to find any benefits associated with corticos-
teroid therapy (Boudreault 2011; Wu 2012). The inclusion cri-
teria in these studies included any influenza-related hospital ad-
mission or intensive care unit (ICU) admission, severe respiratory
failure (adult respiratory distress syndrome (ARDS) or requiring
mechanical ventilation), septic shock, multi-organ failure or ’crit-
ical illness’. However, it was not clear why some patients within
these cohorts received systemic corticosteroid therapy while others
did not. In particular, whether corticosteroid therapy was initiated
primarily for treatment of unstable co-morbid illnesses (including
asthma and chronic obstructive pulmonary disease (COPD)) was
not apparent.
Primary outcomes
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Studies of hospitalised patients
1. Number of deaths at 30 days following admission (30-day
mortality)
Due to heterogeneity in studies reporting timing of mortality from
hospital admission, stratification by 30-day mortality was not pos-
sible as stated in the protocol (Table 3). We graded the quality of
the evidence specific tomortality as very low (Summary of findings
for the main comparison) (GRADE 2011). Meta-analysis of 13
studies (n = 1917 patients) revealed a significant increase in the
odds of mortality with corticosteroid use, with substantial statisti-
cal heterogeneity (odds ratio (OR) 3.06, 95% confidence interval
(CI) 1.58 to 5.92; I2 statistic = 80%) (Analysis 1.1; Figure 2).
Subgroup analysis of unadjusted and adjusted estimates of mortal-
ity showed a similar association with corticosteroid therapy (OR
2.99, 95% CI 1.18 to 7.57; I2 statistic = 86% (Analysis 1.1.1.)
and OR 2.82, 95% CI 1.61 to 4.92 (Analysis 1.1.2); I2 statistic =
0%, respectively). The test for subgroup differences between ad-
justed and unadjusted mortality was not statistically significant (P
value = 0.92). There was no clear indication of publication bias
on funnel plot analysis (Figure 3).
Figure 2. Meta-analysis of studies reporting mortality
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Figure 3. Funnel plot of studies reporting mortality
Two studies reported adjusted hazard ratios (HRs) for mortality
associatedwith corticosteroid therapy; the first reported harm (HR
2.59, 95% CI 1.42 to 4.73) (Brun-Buisson 2011), while the sec-
ond study found no association (HR 1.06, 95% CI 0.63 to 1.80)
(Diaz 2012).
2. Rate of admission to intensive care units
Studies reporting outcomes other than mortality are summarised
in Table 4. Of the studies that were not conducted entirely in an
ICU setting (n = 12), two studies reported composite outcomes
including ICU admission (’critical disease’), which were stratified
according to corticosteroid therapy (Han 2011; Jain 2009). We
graded the quality of the evidence specific to ’critical disease’ as
very low (Summary of findings for the main comparison). A retro-
spective cohort study in the USA of individuals hospitalised with
2009 influenzaAH1N1virus (H1N1pdm09) infection reported a
greater risk of critical care admission/death (unadjusted OR 2.37,
95% CI 1.29 to 4.37) associated with corticosteroid therapy (Jain
2009). In the other retrospective cohort study from China, the
risk of critical disease (defined as death, respiratory failure, septic
shock, failure or insufficiency of ≥ two non-pulmonary organs,
mechanical ventilation or ICU admission) adjusted for co-morbid
illness, obesity and pregnancy, was greater in the group treated
with corticosteroid therapy (adjusted risk ratio (RR) 2.4, 95% CI
1.3 to 4.4) (Han 2011).
Studies in the community setting
Wedid not identify any studies conducted entirely in a community
setting.
1. Rate of hospitalisation
None of the included studies reported this outcome stratified ac-
cording to corticosteroid use.
2. Time to resolution of symptoms
None of the included studies reported this outcome stratified ac-
cording to corticosteroid use.
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3. 30-day mortality
None of the included studies reported this outcome stratified ac-
cording to corticosteroid use.
Secondary outcomes
For studies of hospitalised patients
1. Hospital re-admission rate at 30 days post-discharge
None of the included studies reported this outcome stratified ac-
cording to corticosteroid use.
2. Number and nature of adverse events secondary to
corticosteroid use, such as incidence of gastrointestinal
bleeding, hospital-acquired infections and metabolic
complications (e.g. hyperglycaemia, hypernatraemia)
A summary of studies reporting nosocomial infections according
to corticosteroid use is provided inTable 5.The unadjusted odds of
nosocomial infection were generally greater in the groups treated
with corticosteroid therapy compared to no corticosteroid. We
graded the quality of the evidence related to hospital-acquired in-
fection as very low (Summary of findings for themain comparison)
3. Proportion of patients requiring mechanical ventilation
Two studies reported greater unadjusted odds for mechanical ven-
tilation in the group treated with corticosteroid therapy (Kim
2011; Linko 2011) (Table 4).
4. Length of stay in hospital
Four studies reported length of stay according to corticosteroid
use; all were unadjusted for disease severity (Table 4). Two studies
found a longer length of stay associated with corticosteroid use
(Kim 2011; Linko 2011), while the others reported no statistically
significant difference (Brun-Buisson 2011; Kudo 2012).
For studies in the community setting
1. Number and nature of adverse events secondary to
corticosteroid use
None of the included studies reported this outcome stratified ac-
cording to corticosteroid use.
Sensitivity analysis
Pooled analysis of 12 studies investigating individuals with 2009
influenza A H1N1 virus (H1N1pdm09) infection only, excluding
one study of influenzaA/H5N1 (Liem 2009), found corticosteroid
use to be associated with greater odds of mortality (OR 2.98, 95%
CI 1.47 to 6.04) with high statistical heterogeneity (I2 statistic =
81%).
Subgroup analysis
A summary of outcomes according to the different corticosteroid
regimens is in Table 6; the number of studies was insufficient to
perform subgroup analyses according to the various reported reg-
imens. Only one study compared low versus high doses of corti-
costeroid treatment (Xi 2010). Two studies compared early verus
later/no corticosteroid treatment; one defined early treatment as
within three days of mechanical ventilation (Brun-Buisson 2011),
and the other as within three days from onset of symptoms (Han
2011). Outcomes stratified according to age groups (children ver-
sus adults) and route of corticosteroid administration (intravenous
versus oral) were not reported in the studies included in this re-
view.
Impact of systemic corticosteroid use prior to the
diagnosis of influenza
A study of corticosteroid use for the treatment of graft versus host
disease in haematopoietic stem cell transplant (HSCT) recipients,
in the two weeks prior to the diagnosis of seasonal influenza, found
no observed differences in time to death between individuals re-
ceiving low-dose corticosteroid therapy (< 1mg/kg/day of methyl-
prednisolone) (adjusted HR 1.1, 95% CI 0.4 to 3.6) or high-dose
corticosteroid therapy (≥ 1 mg/kg/day of methylprednisolone)
(adjusted HR 1.1, 95% CI 0.3 to 3.5), in comparison to no prior
corticosteroid therapy (Boudreault 2011). A mixed cohort of out-
patients and in-patients with seasonal influenza reported increased
odds of ’complicated influenza’ (defined as the need for hospital-
isation due to pneumonia, neurological complications, invasive
bacterial infection,myocarditis or pericarditis) associatedwith cor-
ticosteroid therapy (adjusted OR 12.19, 95% CI 3.26 to 45.53)
(Wu 2012). Corticosteroid therapy in the 90 days prior to hos-
pital admission was independently associated with poor outcome
(defined as a composite outcome of ICU admission and death)
(adjusted OR 3.37, 95% CI 1.39 to 8.20) in a study of individuals
hospitalised with 2009 influenza A H1N1 virus (H1N1pdm09)
infection (Delgado-Rodriguez 2012).
D I S C U S S I O N
Summary of main results
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The main findings of this systematic review are that: 1) there are
no completed randomised controlled trials (RCTs) reporting the
impact of adjunctive corticosteroid therapy on clinical outcomes
in patients with influenza infection; the available data from obser-
vational studies are of very low quality, and 2) the available data
suggest corticosteroid therapy might be associated with up to a
three-fold greater odds of mortality. These results should be inter-
preted with caution.
Overall completeness and applicability of
evidence
The findings from this review must be viewed in the light of
two important considerations. Firstly, the indications for corticos-
teroid therapy were not fully specified inmany studies. In some in-
stances, the stated rationalewas adult respiratory distress syndrome
(ARDS) and septic shock (Brun-Buisson 2011; Diaz 2012; Kim
2011; Xi 2010). However, at one extreme, corticosteroid therapy
may have been used as ’a last attempt’ in individuals with refractory
illness. Conversely, theymay have been used to treat less severe un-
derlying comorbid illnesses such as exacerbations of asthma. The
majority of studies included in this review relate to the 2009 pan-
demic when revised guidance from the World Health Organiza-
tion (WHO) in February 2010 would have applied (WHO2010).
However, adherence to that guidance, which recommended that
“patients who have severe or progressive clinical illness, including
viral pneumonitis, respiratory failure and ARDS due to influenza
virus infection, should not be given systemic corticosteroids unless
indicated for other reasons or as part of an approved research pro-
tocol” is not known. Over the same period, the ’Surviving Sepsis
Campaign’ recommended the use of corticosteroid therapy only
in the setting of vasopressor-dependent septic shock (Dellinger
2013). The use of corticosteroids in the context of influenza in-
fection, but for different clinical indications (notably asthma), has
been previously shown to be associated with different outcomes
(Myles 2013); this may reflect both the different mechanisms of
action of corticosteroids depending on the underlying pathophys-
iology and the impact of bias by indication in reports from ob-
servational studies. This is compounded by the lack of consistent
adjustment for disease severity across available studies.
The second consideration relates to the doses of corticosteroids
used. These were poorly specified in many instances and, where
reported, a higher daily dose was used (prednisolone equivalent
> 50 mg daily) than is typically recommended for the treatment
of septic shock or exacerbations of airways disease such as asthma
(BTS 2008; Dellinger 2013; NICE 2010). Variability in corticos-
teroid dose and administration schedule are both factors associated
with treatment outcomes in the setting of severe sepsis; in particu-
lar, high doses given in short bursts have not been associated with
benefit compared to low doses given for longer durations (≥ five
days) (Annane 2009). The use of higher doses of corticosteroids
may explain the greater risk from secondary bacterial pneumonias
due to S. aureus,K. pneumoniae,A. baumannii and P. aeruginosa
observed with corticosteroid therapy in some studies (Kim 2011).
In a study elsewhere, corticosteroid use was also found to be an
independent risk factor for the development of invasive fungal in-
fections in adults admitted to the intensive care unit (ICU) with
influenza (Wauters 2012).
The mechanisms behind potential harm from corticosteroids,
aside from the risks from nosocomial infections, are not well de-
fined. In patients with influenza A (H3N2) infection, systemic
corticosteroid use for exacerbations of asthma or chronic obstruc-
tive pulmonary disease (COPD) was found to be associated with
delayed viral clearance (Lee 2009). A study of individuals hospi-
talised with 2009 influenza A H1N1 virus (H1N1pdm09) infec-
tion found that corticosteroid therapy was associated with persis-
tent viral shedding (defined as the detection of virus on real-time
polymerase chain reaction (RT-PCR) at day seven after diagnosis
on nasopharyngeal swabs) (Giannella 2011). A similar observation
was made in haematopoietic stem cell transplant recipients with
2009 influenza A H1N1 virus (H1N1pdm09) infection (Choi
2011). In turn, slower clearance of viral load was associated with
mortality from ARDS in patients with 2009 influenza A H1N1
virus (H1N1pdm09) infection (To 2010). Though causation can-
not be inferred from these studies, exposure to systemic corticos-
teroids without concurrent antiviral treatment, as was likely for
some patients in the studies reviewed, may proffer the highest risk
of harm (Jain 2009; Wu 2012).
There was no evidence of publication bias in the effect of corticos-
teroids on the odds of mortality, where we found that the treat-
ment effects in smaller studies were similar to those estimated in
the larger studies. Although the test was likely to have sufficient
power from including 13 studies in the funnel plot, we acknowl-
edge their limitation of being subjective.
Quality of the evidence
The pooled analysis of mortality showed high statistical hetero-
geneity, most likely due to the inclusion of unadjusted estimates
of mortality. Clinical heterogeneity was apparent across included
studies. Specifically, disease severity was measured using a wide va-
riety of clinical risk scores and mortality was reported at different
time points; the rationale for corticosteroid use was inconsistent
across studies; there was variation in the treatment groups with
regard to the timing, dosage, duration and type of corticosteroid
used; and the co-interventions for the comparator groups across
studies were not uniform as varying proportions of adults were
treated with antivirals and/or antibiotics. We graded the overall
quality of the evidence for mortality, adverse events, rate of me-
chanical ventilation and critical disease as ’very low’ due to the high
likelihood of indication bias, and clinical and statistical hetero-
geneity in the included observational studies (Summary of findings
for the main comparison).
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Potential biases in the review process
The available evidence identified consists solely of observational
data.We noted a high degree of correlation between corticosteroid
therapy and potential confounders for measured outcomes (such
as disease severity and the presence of co-morbid illness) in some
studies (Kim 2011; Linko 2011; Viasus 2011); hence unadjusted
effect estimates are likely to be confounded by indication.
Agreements and disagreements with other
studies or reviews
A large, multicentre, prospective cohort study of 220 individuals
admitted to ICUs across Europe with 2009 influenza A H1N1
virus (H1N1pdm09) infection was not included in this review
due to overlapping study populations; it found no association be-
tween corticosteroid use and ICU admission and ICU mortal-
ity, following adjustment for age, co-morbid illnesses and disease
severity (adjusted HR 1.3, 95% CI 0.7 to 2.4, P value = 0.4)
(Martin-Loeches 2011).
The association of increased odds of mortality with adjunctive
corticosteroid therapy, as found in this review, is also in contrast
to the evidence base from clinical trials of corticosteroids in the
setting of sepsis and pneumonia. Specifically, in a meta-analysis
of 17 RCTs (n = 2138) of corticosteroids in severe sepsis, sub-
group analysis found that prolonged low-dose corticosteroid ther-
apy was associated with lower 28-day mortality (Annane 2009).
Similarly, a meta-analysis of 12 RCTs (n = 1974) of adults with
community-acquired pneumonia concluded that adjunctive corti-
costeroid therapy may reduce mortality, need for mechanical ven-
tilation and hospital length of stay (Siemieniuk 2015). Larger tri-
als of corticosteroid therapy in severe sepsis and severe pneumonia
are in progress and should provide more robust data within the
next few years (Bos 2012; Bridges 2011; Venkatesh 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available evidence from observational studies is of low quality
with confounding by indication a major potential concern. We
do not have sufficient evidence in this review to determine the
effectiveness of corticosteroids for patients with influenza. There
is a need for more robust evidence on the role of corticosteroids in
the management of influenza before a firm recommendation for
clinical practice can be made.
Implications for research
The most important need is for high-quality, blinded randomised
controlled trials (RCTs), whichwillminimise the biases inherent in
observational designs and thereby provide the necessary evidence
base to inform future clinical practice. Future observational studies
investigating corticosteroids for the treatment of influenza should
state the precise rationale for the administration of corticosteroid
therapy in study participants (such as treatment of complications
of influenza, co-morbid illness or use solely as adjunctive therapy).
The regimens of corticosteroid therapy should be explicitly stated
with regards to the dose, timing of initiation and duration of ther-
apy, and differences in regimens need to be considered when inter-
preting the results of studies. Differences in the administration of
co-interventions between the corticosteroid treated and untreated
groups, including antiviral drugs and antibiotics, also need to be
accounted for. Outcome measures need to be adjusted for poten-
tial confounders including imbalances in baseline characteristics
and disease severity at the very least. A meta-analysis of individual
patient level data from observational studies may be able to over-
come some of the inconsistencies across study-level data.
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Methods Multicentre, prospective cohort study
Participants Country: India (Tamil Nadu)
Setting: in-hospital
Number of individuals: 1302 (280 included in case-control analysis)
Inclusion criteria: individuals with laboratory-confirmed influenza
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age of cohort (years): 26 (IQR 1 to 82)
Female sex: 666 (51%)
Interventions Groups: corticosteroids (n = 70) and no corticosteroids (n = 210)
Outcomes Mortality
Risk of bias (Newcastle-Ottawa Scale) Mortality
Selection domain score (max 4): 2
Comparability domain score (max 2): 1 (no adjustment for disease severity)
Outcome domain score (max 3): 2
Notes -
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senting with respiratory tract infections
Definition of influenza: laboratory-confirmed
Influenza type: seasonal
Median age (years): cohort 42.0 (IQR 31.0 to 53.0); no CS group 42.0 (IQR 32.0 to 51.
0); low-dose CS group 42.0 (IQR 28.0 to 53.0); high-dose CS group 40.0 (IQR 32.0 to 54.
0)
Male sex: cohort 83 (58.0); no CS group 36 (57.0); low-dose CS group 29 (67.0); high-
dose CS group 18 (49.0)
Interventions Groups: highest CS dose in 2/52 preceding influenza diagnosis. No CS (n = 63); low-
dose CS (n = 43); high-dose CS (n = 37)
Definitions for dose: low-dose (prednisolone/methylprednisolone < 1 mg/kg/day); high-
dose (prednisolone/methylprednisolone >= 1 mg/kg/day)
Co-interventions: antiviral therapy
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Boudreault 2011 (Continued)
Outcomes Time to death/time to influenza-associated death: hazard ratios presented following mul-
tivariate analysis. Variables in the multivariate models included CS treatment, antiviral ther-
apy and lymphocyte count
Hypoxaemia
Lower respiratory tract disease
Mechanical ventilation
Adverse events: prolonged viral shedding
Risk of bias (Newcastle-Ottawa Scale) Time to death
Selection domain score (max 4): 2
Comparability domain score (max 2): 1 (no adjustment for age/disease severity)
Outcome domain score (max 3): 2
Notes -
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Adverse events (ICU-acquired infections)
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Brun-Buisson 2011 (Continued)
Risk of bias (Newcastle-Ottawa Scale) In-hospital mortality
Selection domain score (max 4): 3
Comparability domain score (max 2): 2
Outcome domain score (max 3): 3
Length of ICU stay
Selection domain score (max 4): 3
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
ICU-acquired infection
Selection domain score (max 4): 3
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes -
Chawla 2013
Methods Single-centre, retrospective cohort study
Participants Country: India (New Delhi)
Setting: ICU
Number of individuals: 77
Inclusion criteria: individuals with laboratory-confirmed influenza
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age (years): cohort 41 (10 to 72)
Male sex: cohort 44 (57.1)
Interventions Groups: CS (n = 38) versus no CS (n = 39)
Outcomes Mortality
Risk of bias (Newcastle-Ottawa Scale) Mortality
Selection domain score (max 4): 3
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes -
Delgado-Rodriguez 2012
Methods Multicentre, prospective cohort
Participants Country: Spain (Andalusia, Catalonia, Castile and Leon, Madrid, Navarre, the Basque
Country and Valencia)
Setting: in-hospital
Number of sites: 36
Number of individuals: 813
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Delgado-Rodriguez 2012 (Continued)
Inclusion criteria: influenza-like illness, acute respiratory tract infection, septic shock,multi-
organ failure
Exclusion criteria: nosocomial influenza infection
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age (years): cohort 41.0 (IQR 19.0 to 55.0); not reported for individual treatment
groups
Female sex: cohort 410 (50.4); not reported for individual treatment groups
Co-morbid illness: no data for individual CS groups
Disease severity: not reported
Interventions Groups: CS use 90 days prior to admission (n = 31) versus no prior CS use (n = 782)
Outcomes Reported independent association between CS use with poor outcome (composite outcome
of ICU admission and in-hospital death) and length of stay
Risk of bias (Newcastle-Ottawa Scale) ICU admission and mortality
Selection domain score (max 4): 3
Comparability domain score (max 2): 2
Outcome domain score (max 3): 3
Notes Study reporting outcomes according to pre-admission antibiotic use
Diaz 2012
Methods Multicentre, retrospective analysis of prospectively collected data
Participants Country: Spain (voluntary ICU registry)
Setting: ICU
Number of sites: 148
Number of individuals: 372
Inclusion criteria: influenza-like illness; respiratory failure requiring ICU admission; mi-
crobiological confirmation of influenza
Exclusion criteria:
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Mean age (years): cohort 43.4 (± 13.3); no CS group 43.6 (± 13.6); CS group 43.1 (12.9)
Male sex: cohort 205 (55.1); no CS group 69 (57.6); CS group 69 (50.7)
Co-morbid illnesses: asthma - no CS 7.6 (18), CS 15.4 (21); COPD - no CS 11.4 (27),
CS 13.2 (18)
Disease severity (Mean Acute Physiology and Chronic Health Evaluation Score II score
(APACHE II)): cohort 12.8 (± 6.5); no CS group 12.5 (± 6.7); CS group 13.2 (± 6.3) (P
value = 0.318 for 2 groups)
Interventions Groups: CS (n = 136) versus no CS (n = 236) treatment
Data regarding dose, duration and timing not available
Co-interventions: antiviral therapy administered to all
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Diaz 2012 (Continued)
Outcomes ICU mortality: presented as adjusted hazard ratios adjusted for severity and co-morbid
illness (asthma, chronic kidney disease, morbid obesity, haematological disease) using Cox
regression analysis
Length of stay (hospital and ICU presented separately)
Mechanical ventilation
Risk of bias (Newcastle-Ottawa Scale) ICU mortality
Selection domain score (max 4): 3
Comparability domain score (max 2): 2
Outcome domain score (max 3): 3
Notes -
Han 2011
Methods Multicentre, retrospective cohort
Participants Country: China (Shenyang City)
Setting: in-hospital
Number of sites: 4
Number of individuals: 83
Inclusion criteria: age > 3 years
Exclusion criteria:
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age (years): no CS group 38 (IQR 5 to 75); CS group 43 (IQR 3 to 70)
Male sex: no CS group 18 (49.0); CS group 29 (63.0)
Co-morbid illnesses: not reported individually
Disease severity:Median Pandemic Medical Early Warning Score (PMEWS): no CS group
2 (IQR 0 to 5); CS group 2 (0 to 5)
Interventions Groups: no CS group (n = 37) versus CS group (n = 46)
CS group further subdivided into early treatment (<= 72 hours n = 17) and late treatment
(> 72 hours n = 29)
Type: methylprednisolone and dexamethasone
Co-interventions: antivirals
Outcomes Critical illness: defined as >= 1 of the following: death, respiratory failure, septic shock,
failure or insufficiency of >= 2 non-pulmonary organs, mechanical ventilation or ICU ad-
mission
A proportional hazards model was used to estimate the probability of developing critical
disease after controlling for the presence of underlying co-morbid illnesses and presence of
risk factors (age >= 65 years, pregnancy, obesity)
Risk of bias (Newcastle-Ottawa Scale) Critical illness
Selection domain score (max 4): 3
Comparability domain score (max 2): 2
Outcome domain score (max 3): 3
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Han 2011 (Continued)
Notes Study also compared outcomes with regard to timing of CS initiation (< 72 hours versus >
72 hours)
Jain 2009
Methods Multicentre, retrospective cohort
Participants Country: USA
Setting: in-hospital
Number of sites: national surveillance data
Number of individuals: 272 (CS data available for 239)
Inclusion criteria: individuals hospitalised with influenza-like illness
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age (years): cohort 21 years (IQR, 21 days to 86 years)
Male sex: not reported for CS groups
Co-morbid illnesses: not reported for CS groups
Disease severity: not reported for CS groups
Interventions Groups: no CS (n = 153); CS (n = 86)
Type: not reported
Co-interventions: antivirals 200/268 (74.6); antibiotics 206/260 (79.2)
Outcomes Death/ICU admission versus survival/no ICU admission
Risk of bias (Newcastle-Ottawa Scale) Death/ICU admission versus survival/no ICU admission
Selection domain score (max 4):
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes -
Kim 2011
Methods Multicentre, retrospective cohort/case-control
Participants Country: Korea
Setting: ICU
Number of sites: 28
Number of individuals: 245
Inclusion criteria: age >= 15 years; presence of critical illness defined as i) admitted to ICUor
required mechanical ventilation (invasive or non-invasive), or ii) had ratio of partial pressure
of oxygen in arterial blood (PaO2) to inspired fraction of oxygen (FiO2) less than 300
mmHg, or iii) required intravenous infusion of an inotropic or vasoconstrictive medication)
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Mean age (years): no CS group 54.1 (± 19.3); CS group 56.9 (± 17.2)
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Kim 2011 (Continued)
Male sex: no CS group 73 (53.0); CS group 61 (57.0)
Co-morbid illnesses:
Asthma: CS 10 (9); no CS 9 (7)
COPD: CS 14 (13); no CS 6 (4)
Solid tumour: CS 30 (28); no CS 19 (14)
Disease severity (Mean Acute Physiology and Chronic Health Evaluation Score II
(APACHE II)): no CS group 17.5 (± 8.5); CS group 21.2 (± 7.7); P value = 0.001
Interventions Groups: CS treatment (n = 107) versus no CS treatment (n = 138)
Dose: median prednisolone equivalent 75 (IQR 50 to 81) mg/day
Duration of treatment: median 6 (IQR 6 to 13) days
Antibiotics: CS group 107 (100.0); no CS group 136 (99.0)
Antivirals: CS group 44 (41.0); no CS group 68 (49.0)
Outcomes Mortality:14-day, 30-day and 90-day mortality reported. Adjusted estimates presented for
90-day mortality (following adjustment for age, SOFA score, mechanical ventilation, lym-
phocyte count and propensity score)
Unadjusted estimates given for mechanical ventilation and length of stay
Adverse events: secondary bacterial infections
Risk of bias (Newcastle-Ottawa Scale) Mortality
Selection domain score (max 4): 4
Comparability domain score (max 2): 2
Outcome domain score (max 3): 3
Mechanical ventilation
Selection domain score (max 4): 4
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Length of stay
Selection domain score (max 4): 4
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Hospital-acquired infection
Selection domain score (max 4): 4
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes Adjusted estimates for 90-day mortality presented following logistical regression in a cohort
study. Separate estimates given in a propensity matched case-control study
Kudo 2012
Methods Single-centre, retrospective cohort
Participants Country: Japan
Setting: in-hospital
Number of individuals: 89
Inclusion criteria: hospitalised patients with respiratory disorders (upper respiratory tract
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Kudo 2012 (Continued)
infection, wheezing illness, pneumonia with wheezing and pneumonia without wheezing)
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age (years): 8 (IQR 0 to 71) for cohort
Male sex: 45 (50.6) in cohort
Co-morbid illnesses: asthma: cohort 26 (29.2)
Disease severity: not reported
Interventions Groups: CS treatment (n = 46) versus no CS treatment (n = 12) *based on 58 individuals
in cohort
Dose: methylprednisolone 1 to 1.5 mg/kg, 2 to 4 times/day
Duration of treatment: median 5.1 days
Timing of treatment: median 2.1 days following symptom onset
Antibiotics: n = 63 (70.8) given antibiotics in cohort
Antivirals: all individuals received antiviral therapy
Outcomes Length of stay
Risk of bias (Newcastle-Ottawa Scale) Length of stay
Selection domain score (max 4): 4
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes -
Li 2012
Methods Multicentre, retrospective cohort
Participants Country: China (Anhui province)
Setting: in-hospital
Number of sites: not known
Number of individuals: 46
Inclusion criteria: pregnant, severe disease (defined as high fever for > 3 days, haemoptysis
with purulent sputum, chest pain, dyspnoea, cyanosis, altered mental state, severe vomiting,
diarrhoea and dehydration, radiologically confirmed pneumonia, elevated cardiac enzymes,
respiratory failure, sepsis, multi-organ dysfunction or admission to intensive care units
Exclusion criteria:dischargewithin 24hours, individualsmanaged in the out-patient setting
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age (years): adults who died 21 (IQR 18 to 31) and survivors 21 (IQR 18 to 27)
Female sex: 46 (100.0)
Disease severity: not reported
Interventions Groups: CS treatment (n = 27) versus no CS treatment (n = 19)
Dose: not reported
Duration of treatment: not reported
Antibiotics: not reported
Antivirals: all given antivirals
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Li 2012 (Continued)
Outcomes Mortality
Risk of bias (Newcastle-Ottawa Scale) Mortality
Selection domain score (max 4): 2
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes -
Liem 2009
Methods Multicentre, retrospective cohort
Participants Country: Vietnam
Setting: in-hospital
Number of individuals: 67
Inclusion criteria: all hospitalised patients with influenza A (H5N1) infection
Definition of influenza: laboratory-confirmed
Influenza type: A/H5N1
Age, median years: cohort 25 (IQR 16 to 42)
Male sex: cohort 37 (55.0)
Co-morbid illnesses: not reported
Interventions Groups: CS treatment (n = 29) versus no CS treatment (n = 38)
Dose: methylprednisolone 1 to 3 mg/kg/day
Duration of treatment: up to 7 days
Antibiotics: given to 63 (94.0) of cohort
Antivirals: given to 55 (82.0) of cohort
Outcomes In-hospital mortality
Adjusted for the presence or absence of neutropenia as a marker of disease severity to inves-
tigate the effect of steroid treatment on outcome
Risk of bias (Newcastle-Ottawa Scale) In-hospital mortality
Selection domain score (max 4): 4
Comparability domain score (max 2): 1
Outcome domain score (max 3): 3
Notes -
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Linko 2011
Methods Multicentre, prospective cohort
Participants Country: Finland
Setting: ICU
Number of individuals: 132
Inclusion criteria: ICU admissions with influenza
Definition of influenza: high clinical suspicion or laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age (years): no CS group 44 (IQR 25 to 57); CS group 51 (40 to 56)
Male sex: no CS group 39 (65.0); CS group 46 (64.0)
Co-morbid illnesses:
COPD: no CS 3 (5); CS 6 (8)
Other obstructive pulmonary disease: no CS 14 (23); CS 15 (21)
Disease severity (median IQR): Simplified Acute Physiology score II (SAPS II) no CS
group 22 (15 to 30), CS group 31 (24 to 36). Sequential Organ Failure Assessment score
(SOFA) no CS group 3 (2 to 6); CS group 6 (2 to 8); P value < 0.01
Interventions Groups: CS treatment (n = 72) versus no CS treatment (n = 60)
Type of steroid: methylprednisolone and/or hydrocortisone
Dose: mean (SD) of the highest methylprednisolone dose was 94 (± 43) mg and hydrocor-
tisone 214 (± 66) mg
Timing of steroid therapy: median (IQR) days after symptom onset 5.0 (2.8 to 8.3)
Co-interventions: antibiotics (84% of cohort); antivirals (96% of cohort)
Outcomes Hospital mortality: odds ratios given following adjustment for disease severity (SAPS II)
Unadjusted estimates given for mechanical ventilation and length of stay
Risk of bias (Newcastle-Ottawa Scale) Hospital mortality
Selection domain score (max 4): 4
Comparability domain score (max 2): 2
Outcome domain score (max 3): 3
Mechanical ventilation
Selection domain score (max 4): 4
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Length of stay
Selection domain score (max 4): 4
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes -
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Mady 2012
Methods Single-centre, retrospective cohort
Participants Country: Saudi Arabia
Setting: ICU
Number of individuals: 86
Inclusion criteria: influenza with respiratory failure
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Mean age (years): cohort 40.8. Not reported for treatment groups
Male sex: cohort 64 (74.4). Not reported for treatment groups
Co-morbid illnesses: cohort 33 (38.3)
Disease severity (mean APACHE IV score): cohort 105.6 (41 to 190); CS group versus no
CS group 110.5 versus 100.6 (P value > 0.05) *NB not specified for which treatment group
in article
Interventions Groups: CS treatment (n = 43) versus no CS treatment (n = 43)
Type of steroid: methylprednisolone
Dose: 1 mg/kg per day for 7 days
Timing of steroid therapy: not reported
Outcomes In-hospital mortality: unadjusted estimates
Risk of bias (Newcastle-Ottawa Scale) Selection domain score (max 4): 3
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes -
Patel 2013
Methods Single-centre, retrospective cohort study
Participants Country: India (Gujarat)
Setting: in-hospital
Number of individuals: 63
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age (years): 34 (IQR 3 to 69)
Male sex: 41 (65%)
Interventions Groups: CS treatment (n = 39); no CS treatment (n = 24)
Type of steroid: methylprednisolone
Dose: 40 mg 3 times daily for 1 week, twice daily for 1 week and once daily for 1 week
Route of administration: intravenous
Timing of steroid therapy: not reported
Outcomes Mortality
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Patel 2013 (Continued)
Risk of bias (Newcastle-Ottawa Scale) Selection domain score (max 4): 2
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes -
Sertogullarindan 2011
Methods Single-centre, prospective cohort
Participants Country: Turkey
Setting: ICU
Number of individuals: 20
Inclusion criteria: ICU admissions with severe community-acquired pneumonia and in-
fluenza
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age (years): cohort 36 (IQR 15 to 72); not reported by CS treatment groups
Male sex: cohort 10 (50.0); not reported by CS treatment groups
Co-morbid illnesses:
COPD: cohort 2 (10)
Malignancy: cohort 2 (10)
Disease severity: not reported
Interventions Groups: CS treatment versus (n = 11) no CS treatment (n = 9)
Co-interventions: antibiotics (90% of cohort); antivirals (100% of cohort)
Outcomes Mortality (unadjusted estimates)
Risk of bias (Newcastle-Ottawa Scale) Selection domain score (max 4): 3
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes -
Viasus 2011
Methods Multicentre, prospective cohort study
Participants Country: Spain
Setting: in-hospital
Number of sites: 13
Number of individuals: 197
Inclusion criteria: non-immunosuppressed individuals admitted for at least 24 hours with
influenza A
Exclusion criteria: chemotherapy/solid organ transplant/HIV/neutropenia/ICU admission
on admission to hospital
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Viasus 2011 (Continued)
Definition of influenza: laboratory-confirmed (PCR or culture)
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Median age (years): no CS group 35 (IQR 28 to 47); CS group 44 (IQR 36 to 53)
Male sex: no CS group 73 (53.0); CS group 61 (57.0)
Co-morbid illnesses: chronic pulmonary disease: no CS 22 (17.1); CS 17 (45.9)
Disease severity: number of individuals in high risk Pneumonia Severity Index (PSI) risk
classes: CS group 8 (21.6) and no CS group 8 (6.4); P value < 0.05
Interventions Groups: compared adults receiving immunomodulatory therapy (n = 68) (CS (n = 37),
statins (n = 12) or macrolides (n = 31)) versus adults not receiving immunomodulatory
therapy (n = 129)
Duration: median days 9 (5 to 13.5)
Outcomes In-hospital mortality
Hospital-acquired infection
Risk of bias (Newcastle-Ottawa Scale) In-hospital mortality
Selection domain score (max 4): 4
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Hospital-acquired infection
Selection domain score (max 4): 4
Comparability domain score (max 2): 0
Outcome domain score (max 3): 3
Notes -
Wu 2012
Methods Single-centre, prospective cohort
Participants Country: Taiwan
Setting: mixed cohort of out-patients and in-patients
Number of individuals: 206
Inclusion criteria: > 16 years with influenza-like illness. Compared complicated (requiring
hospital admission) versus uncomplicated influenza (n = 176)
Exclusion criteria: not reported
Definition of influenza: laboratory-confirmed
Influenza type: seasonal influenza
Age >= 65 years: cohort 26 (12.6)
Male sex: cohort 110 (53.4)
Co-morbid illness:
Chronic lung disease: cohort 20 (9.7)
Malignancy: cohort 18 (8.7)
Disease severity: complicated influenza (n = 30) and uncomplicated influenza n = 176
Interventions Groups: CS therapy use n = 17; no CS use n = 189
Unclear if CS was used prior to or following diagnosis
Dose/timing/duration: not reported
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Wu 2012 (Continued)
Antiviral therapy: cohort 68 (33.0)
Outcomes Complicated influenza (adjusted for age, co-morbid illnesses, clinical features, laboratory
findings and CS use)
Risk of bias (Newcastle-Ottawa Scale) Complicated influenza
Selection domain score (max 4): 4
Comparability domain score (max 2): 1
Outcome domain score (max 3): 3
Notes -
Xi 2010
Methods Multicentre, retrospective cohort study
Participants Country: China (Beijing)
Setting: in-hospital
Number of sites: 23
Number of individuals: 155
Inclusion criteria: adults aged >= 18 years admitted to hospital
Definition of influenza: laboratory-confirmed
Influenza type: 2009 influenza A H1N1 virus (H1N1pdm09)
Mean (SD) age (years): cohort 43 (± 18.6)
Male sex: cohort 90 (58.1)
Co-morbid illness: chronic obstructive pulmonary disease: cohort 10 (6.5%)
Disease severity: acute respiratory failure (24/103 (23.3%) in the no CS group versus 38/
52 (73.1%) in the CS group); septic shock (5/103 (4.9%) in the no CS group versus 13/
103 (25.0%) in the CS group); invasive ventilation (16/103 (15.5%) in the no CS group
versus 27/52 (51.9%) in the CS group)
Interventions Groups: primary comparison was survivors versus non-survivors. Secondary comparison
made of CS treatment (n = 52) versus no CS treatment (n = 103)
Dose: daily median dose equivalent to 80mg (IQR 80mg to 160mg) of methylprednisolone
Co-interventions: antivirals given to n = 132 (85.2) of cohort; antibiotics 139 (89.7) of
cohort
Outcomes Hospital mortality: raw numbers for mortality were derived from data given in article.
Adjusted odds ratio for mortality were given for CS use in multivariate analysis
Adjustment was made for ethnicity, co-morbid illness (hypertension, diabetes), symptoms
at disease onset (dyspnoea, sore throat), clinical presentation (dyspnoea), laboratory testing
(lactate dehydrogenase) and CS treatment, in the multivariate analysis
No difference in mortality for low-dose (< 80 mg of methylprednisolone) versus high-dose
CS in a subgroup analysis (9/30 versus 8/22, P value = 0.854)
Risk of bias (Newcastle-Ottawa Scale) Selection domain score (max 4): 3
Comparability domain score (max 2): 1
Outcome domain score (max 3): 3
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Xi 2010 (Continued)
Notes -
APACHE: Acute Physiology and Chronic Health Evaluation
COPD: chronic obstructive pulmonary disease
CS: corticosteroid
ICU: intensive care unit
IQR: inter-quartile range
PCR: polymerase chain reaction
SAPS: Simplified Acute Physiology Score
SD: standard deviation
SOFA: Sequential Organ Failure Assessment
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chan 2014 No outcome data comparing corticosteroid treatment versus no corticosteroid treatment
Fujikura 2014 No outcome data comparing corticosteroid treatment versus no corticosteroid treatment
Gao 2013 No outcome data comparing corticosteroid treatment versus no corticosteroid treatment
Garnacho-Montero 2013 Overlapping populations*
Hu 2013 No outcome data comparing corticosteroid treatment versus no corticosteroid treatment
Martin-Loeches 2013 Overlapping populations*
Mckenna 2013 Overlapping populations*
Ning 2014 Fewer than 10 participants in study
Okur 2013 Overlapping populations*
Smud 2010 No outcome data comparing corticosteroid treatment versus no corticosteroid treatment
*Overlapping populations refers to studies where data from cohorts included in the review were duplicated, either due to multiple
reporting of the same cohort, or inclusion of the cohort within the study population of a larger study.
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D A T A A N D A N A L Y S E S
Comparison 1. Corticosteroid therapy versus no corticosteroid therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 13 1917 Odds Ratio (Random, 95% CI) 3.06 [1.58, 5.92]
1.1 Unadjusted mortality 9 1318 Odds Ratio (Random, 95% CI) 2.99 [1.18, 7.57]
1.2 Adjusted mortality 4 599 Odds Ratio (Random, 95% CI) 2.82 [1.61, 4.92]
Analysis 1.1. Comparison 1 Corticosteroid therapy versus no corticosteroid therapy, Outcome 1 Mortality.
Review: Corticosteroids as adjunctive therapy in the treatment of influenza
Comparison: 1 Corticosteroid therapy versus no corticosteroid therapy
Outcome: 1 Mortality
Study or subgroup Corticosteroid group
No corti-
costeroid
group log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Unadjusted mortality
Balaganesakumar 2013 70 210 3.1676 (0.3539) 9.8 % 23.75 [ 11.87, 47.52 ]
Brun-Buisson 2011 83 125 0.9247 (0.3334) 9.9 % 2.52 [ 1.31, 4.85 ]
Chawla 2013 38 39 2.4675 (1.0825) 5.2 % 11.79 [ 1.41, 98.41 ]
Diaz 2012 136 236 0.0688 (0.2802) 10.2 % 1.07 [ 0.62, 1.86 ]
Li 2012 27 19 1.6376 (1.1269) 4.9 % 5.14 [ 0.56, 46.82 ]
Mady 2012 43 43 1.0542 (0.4731) 9.1 % 2.87 [ 1.14, 7.25 ]
Patel 2013 39 24 1.0116 (0.7124) 7.4 % 2.75 [ 0.68, 11.11 ]
Sertogullarindan 2011 11 9 -1.674 (0.9789) 5.7 % 0.19 [ 0.03, 1.28 ]
Viasus 2011 37 129 1.0143 (0.7879) 6.9 % 2.76 [ 0.59, 12.92 ]
Subtotal (95% CI) 484 834 69.1 % 2.99 [ 1.18, 7.57 ]
Heterogeneity: Tau2 = 1.55; Chi2 = 57.84, df = 8 (P<0.00001); I2 =86%
Test for overall effect: Z = 2.31 (P = 0.021)
2 Adjusted mortality
Kim 2011 107 138 0.7885 (0.3872) 9.6 % 2.20 [ 1.03, 4.70 ]
Liem 2009 29 38 1.4134 (0.6543) 7.8 % 4.11 [ 1.14, 14.82 ]
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
(Continued . . . )
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(. . . Continued)
Study or subgroup Corticosteroid group
No corti-
costeroid
group log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Linko 2011 72 60 1.1939 (0.9628) 5.8 % 3.30 [ 0.50, 21.78 ]
Xi 2010 52 103 1.3002 (0.6685) 7.7 % 3.67 [ 0.99, 13.60 ]
Subtotal (95% CI) 260 339 30.9 % 2.82 [ 1.61, 4.92 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.63 (P = 0.00028)
Total (95% CI) 744 1173 100.0 % 3.06 [ 1.58, 5.92 ]
Heterogeneity: Tau2 = 1.03; Chi2 = 58.81, df = 12 (P<0.00001); I2 =80%
Test for overall effect: Z = 3.31 (P = 0.00092)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
A D D I T I O N A L T A B L E S
Table 1. Summary of included studies - studies included in meta-analysis
Study/year
(country)
Design Setting/in-
clusion cri-
teria
CS given
(n)
CS not
given (n)
Demo-
graphics
Dis-
ease sever-
ity scores
Corticos-
teroid ther-
apy dose/
timing/
duration
Outcomes
reported
Influenza 2009 influenza A H1N1 virus (H1N1pdm09)
Balagane-
sakumar
2013 (India
- Tamil
Nadu)
Multicen-
tre, prospec-
tive cohort
study
In-hospital/
admissions
with
influenza
70 210 Median age
(years): 26
(1 to 82)
Not
reported
Not
reported
Mortality
Brun-Buis-
son 2011
(France)
Multicentre,
retrospec-
tive analysis
of prospec-
tively col-
lected data
ICU/severe
res-
piratory fail-
ure (ARDS
or MV)
83 (early CS
50 and late
CS 33)
125 Median age
(years): no
CS 45 (35 to
55); CS 49
(34 to 56)
Immuno-
suppression:
no CS 18.
4%; CS 21.
Median
SAPSIII co-
hort 52.
0 (44.0 to
64.0); noCS
53.0 (46.0
to 66.0); CS
group 51.0
(44.0 to 61.
Median
daily dose:
270 (200 to
400) mg of
hydrocorti-
sone equiva-
lent
Timing:
within me-
Hos-
pital mortal-
ity, length of
ICU
stay, adverse
events
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Table 1. Summary of included studies - studies included in meta-analysis (Continued)
7% 0); P value =
0.25
dian 1 day (0
to 6) of MV
Du-
ration: me-
dian 11 days
(6 to 20)
Chawla
2013 (India
- New
Delhi)
Single-cen-
tre, retro-
spective co-
hort study
ICU/admis-
sions with
influenza
38 39 Mean age
(years): 40.9
(± 13.4)
Not
reported
Duration of
therapy:
mean (days)
10.6 (± 7.8)
Mortality
Diaz 2012
(Spain)
Multicentre,
retrospec-
tive analysis
of prospec-
tively col-
lected data
ICU/
ILI; respira-
tory failure
re-
quiring ICU
admission
136 236 Mean
age (years):
no CS 43.6
(± 13.6); CS
43.1 (12.9)
Asthma: no
CS 18%; CS
21%
COPD: no
CS 27%; CS
18%
Mean (SD)
APACHEII:
no CS group
12.5 (± 6.7)
; CS group
13.2 (± 6.3)
(P value = 0.
318)
Not
reported
ICUmortal-
ity, MV,
LOS
Kim 2011
(South Ko-
rea)
Multicentre,
retrospec-
tive cohort/
case-control
ICU/age ≥
15
years; pres-
ence of criti-
cal illness
107 138 Mean
age (years):
no CS 54.1
(± 19.3); CS
56.9 (± 17.
2)
Asthma: CS
9%; no CS
7%
COPD: CS
13%; no CS
4%
Mean (SD)
APACHE
II:
no CS group
17.5 (± 8.5)
; CS group
21.2 (± 7.7);
P value = 0.
001
Dose:
median pred
equiv-
alent 75 (50
to 81) mg/
day
Duration:
median days
6 (3 to 14)
Mortality
(14-day, 30-
day and 90-
day), LOS,
acquired in-
fections
Li 2012
(China -
Anhui
province)
Mul-
ticentre, ret-
rospective
cohort study
In-hospital/
preg-
nant, severe
disease
27 19 Median age
(years)
: adults who
died 21 (18
to 31) and
survivors 21
(18 to 27)
Not
reported
Not
reported
Mortality
Linko 2011
(Finland)
Multicen-
tre, prospec-
tive cohort
study
ICU/admis-
sions with
influenza
72 60 Median age
(years): no
CS 44 (25 to
57); CS 51
Median
SAPSII: no
CS 22 (15 to
30); CS 31
Methylpred
and/or hy-
drocortisone
Dose: mean
In-hospi-
talmortality,
MV, LOS
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Table 1. Summary of included studies - studies included in meta-analysis (Continued)
(40 to 56)
COPD: no
CS 5%; CS
8%
Other
obstructive
pulmonary
disease:
no CS 23%;
CS 21%
(24 to 36);
P value = 0.
001
(SD) of
high-
est methyl-
pred dose 94
(± 43) mg
and hydro-
corti-
sone 214 (±
66) mg
Timing: me-
dian (IQR)
days af-
ter symptom
onset 5.0 (2.
8 to 8.3)
Mady 2012
(Saudi Ara-
bia)
Single-cen-
tre, retro-
spective co-
hort study
ICU/
influenza
with respira-
tory failure
43 43 Cohort
mean age
(years): 40.8
Asthma or
COPD: 38.
3%
Mean
APACHEIV:
110.5 versus
100.6 (P
value > 0.
05), not
specified
for which
treatment
group
Methylpred
Dose: 1 mg/
kg per day
for 7 days
Mortality
Patel 2013
(India - Gu-
jarat)
Single-cen-
tre, retro-
spective co-
hort study
In-hospital/
admissions
with
influenza
39 24 Co-
hort median
age (years):
34 (3 to 69)
Not
reported
Dose:
methylpred-
nisolone 40
mg 3 times
a day, twice
a day and
once a day,
for week 1,
2 and 3 re-
spectively
Mortality
Ser-
togullarin-
dan 2011
(Turkey)
Single-cen-
tre, prospec-
tive cohort
study
ICU/severe
community-
acquired
pneumo-
nia and in-
fluenza
11 9 Co-
hort median
age (years):
36 (15 to
72)
COPD:
10%
Not
reported
Not
reported
Mortality
Viasus
2011
(Spain)
Multicen-
tre, prospec-
tive cohort
In-hospi-
tal/ non-im-
munosup-
37 129 Median age
(years): no
CS 35 (28 to
Number
in high-risk
PSI classes:
Duration:
median days
9 (5 to 13.5)
Severe
disease
(composite
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Table 1. Summary of included studies - studies included in meta-analysis (Continued)
study pressed, ad-
mitted > 24
hours
47); CS 44
(36 to 53)
Chronic
pul-
monary dis-
ease: no CS
17.1%; CS
45.9%
CS 8 (21.6);
no CS 8 (6.
4); P value <
0.05
outcome of
ICU admis-
sion/death),
acquired in-
fection
Xi 2010
(China -
Beijing)
Mul-
ticentre, ret-
rospective
cohort study
In-hospi-
tal/age ≥ 18
years
52 103 Cohort
mean
age (years):
43 (± 18.6)
COPD: 6.
5%
Not
reported
Dose: daily
median dose
equivalent
to methyl-
pred 80 mg
(IQR 80 to
160 mg)
In-hospital
mortality
Sub-
group analy-
sis of mor-
tality by CS
dose
Avian
influenza A
(H5N1)
Liem 2009
(Vietnam)
Multicentre,
retrospec-
tive cohort
In-hospital/
hos-
pitalised pa-
tients with
influenza
29 38 Co-
hort median
age (years):
25 (16 to
42)
Not
reported
Dose:
methylpred
1 to 3 mg/
kg/day for 7
days
In-hospital
mortality
Studies not included in meta-analysis
Influenza 2009 influenza A H1N1 virus (H1N1pdm09)
Delgado-
Rodriguez
2012
(Spain)
Multicen-
tre, prospec-
tive cohort
In-hospi-
tal/ILI, RTI,
septic shock,
multi-organ
failure
31 782 Co-
hort median
age (years):
41 (19 to
55)
Not
reported
Corticos-
teroid use 90
days prior to
admission
Poor out-
come (ICU
admission
and in-hos-
pital death),
LOS
Han 2011
(China
- Shenyang
City)
Multicentre,
retrospec-
tive cohort
In-hospital/
age > 3 years
46 (early CS
17 and late
CS 29)
37 Median age
(years)
: no CS 38
(5 to 75); CS
43 (3 to 70)
Median
PMEWS:
no CS group
2 (0 to 5);
CS group 2
(0 to 5)
Methylpred
and dexam-
ethasone
Critical ill-
ness
Jain 2009
(USA)
Multicentre,
retrospec-
tive cohort
In-hospi-
tal/ILI with
hospital
admission ≥
24 hours
86 153 Co-
hort median
age: 21 years
(21 days to
86 years)
Not
reported
Not
reported
Death/ICU
ad-
mission ver-
sus survival/
no ICU ad-
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Table 1. Summary of included studies - studies included in meta-analysis (Continued)
Asthma:
28%;
COPD: 8%
Immuno-
suppression:
15%
mission
Kudo 2012
(Japan)
Single-cen-
tre, retro-
spective co-
hort
In-hospital/
hospitalised
patients
with respira-
tory
disorders
46 12 Co-
hort median
age (years): 8
(0 to 71)
Asthma: 29.
2%
Not
reported
Dose:
methyl-
pred 1 to 1.5
mg/kg, 2 to
4 times/day
Duration:
median 5.1
days
Timing: me-
dian 2.1
days follow-
ing symp-
tom onset
LOS
Interpan-
demic (sea-
sonal)
influenza
Boudreault
2011 (USA)
Single-cen-
tre, retro-
spective co-
hort
Non-ICU/
HSCT
recipients
with RTI
80
(low-dose
43 and high-
dose 37)
63 Median age
(years): no
CS 42 (32
to 51); low-
dose CS 42
(28 to 53)
; high-dose
CS 40 (32 to
54)
Not
reported
Highest
dose in 2/52
preceding
influenza
Low-
dose (pred/
methylpred
< 1 mg/kg/
day); high-
dose (pred/
methylpred
>= 1 mg/kg/
day)
MV, time to
death, PVS
Wu 2012
(Taiwan)
Single-cen-
tre, prospec-
tive cohort
Mixed co-
hort of out-
patients and
in-patients
17 189 Age >= 65
years in co-
hort: 12.6%
Chronic
lung disease:
9.7%
Malignancy:
8.7%
Not
reported
Dose/dura-
tion: not re-
ported
Unclear
if CS com-
menced
prior to
or following
diagnosis
Com-
plicated in-
fluenza (re-
quiring hos-
pitalisation)
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APACHE: Acute Physiology and Chronic Health Evaluation
ARDS: adult respiratory distress syndrome
COPD: chronic obstructive pulmonary disease
CS: corticosteroid therapy
HSCT: haematopoietic stem cell transplant
ICU: intensive care unit
ILI: influenza-like illness
IQR: inter-quartile range
LDH: lactate dehydrogenase
LOS: length of stay
methylpred: methylprednisolone
MV: mechanical ventilation
PMEWS: Pandemic Modified Early Warning Score
pred: prednisolone
PSI: Pneumonia Severity Index
PVS: persistent viral shedding
RTI: respiratory tract infection
SAPS: Simplified Acute Physiology Score
SD: standard deviation
SOFA: Sequential Organ Failure Assessment
Table 2. Risk of bias in observational studies using the Newcastle-Ottawa Scale
Study Outcome Selection domain
(maximum 4 stars)
Comparability domain
(maximum 2 stars)
Outcome domain
(maximum 3 stars)
Balaganesakumar 2013 Mortality 2 1 2
Boudreault 2011 † Time to death 2 1 2
Brun-Buisson 2011 In-hospital mortality 3 2 3
Brun-Buisson 2011 Length of ICU stay 3 0 3
Brun-Buisson 2011 ICU-acquired infection 3 0 3
Chawla 2013 Mortality 3 0 3
Delgado-Rodriguez
2012 †
Composite
outcome of ICU admis-
sion and mortality
3 2 3
Diaz 2012 ICU mortality 3 2 2
Han 2011 † Critical illness 3 2 3
Jain 2009 † ICU admission death
versus survival/no ICU
admission
4 0 3
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Table 2. Risk of bias in observational studies using the Newcastle-Ottawa Scale (Continued)
Kim 2011 Mortality 4 2 3
Kim 2011 MV 4 0 3
Kim 2011 LOS 4 0 3
Kim 2011 Hospital-acquired infec-
tion
4 0 3
Kudo 2012 † LOS 4 0 2
Li 2012 Mortality 2 0 3
Liem 2009 In-hospital mortality 4 1 3
Linko 2011 In-hospital mortality 4 2 3
Linko 2011 MV 4 0 3
Linko 2011 LOS 4 0 3
Mady 2012 Mortality 3 0 3
Patel 2013 Mortality 2 0 3
Sertogullarindan
2011
Mortality 3 0 3
Viasus 2011 In-hospital mortality 4 0 3
Viasus 2011 Hospital-acquired infec-
tion
4 0 3
Wu 2012 † Influenza requiring hos-
pitalisation
4 1 3
Xi 2010 In-hospital mortality 3 1 3
ICU: intensive care unit
LOS: length of stay
MV: mechanical ventilation
† studies not included in meta-analysis (three studies investigating CS therapy before influenza diagnosis (Boudreault 2011; Delgado-
Rodriguez 2012; Wu 2012); three studies with no mortality data according to CS use (Han 2011; Jain 2009; Kudo 2012).
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Table 3. Summary of studies reporting mortality
Study Outcome
reported
Mortality
in CS treatment
group
Mortal-
ity in group not
treated with CS
Reported unad-
justed risk of
mortality
Reported
adjusted risk of
mortality
Variables in-
cluded inmodel
for adjusted es-
timates
Balaganesaku-
mar 2013
Mortality 50/70 (71.4) 20/210 (9.5) OR 23.8 (95%
CI 11.3 to 50.8)
Not reported -
Brun-Buisson
2011
In-hospital mor-
tality
28/83 (33.8) 21/125 (16.8) HR 2.39 (95%
CI 1.32 to 4.31)
aHR 2.59 (95%
CI 1.42 to 4.73)
Immunosup-
pression, disease
severity (SAPS3)
, vasopressor use
Chawla 2013 Mortality 9/38 (23.7) 1/39 (2.6) OR 11.8 (95%
CI 1.4 to 98.4)
Not reported -
Diaz 2012 ICU mortality 25/136 (18.4) 41/236 (17.4) HR 0.91 (95%
CI 0.55 to 1.48)
aHR 1.06 (95%
CI 0.63 to 1.80)
Disease sever-
ity (APACHEII)
, co-morbid ill-
nesses
Kim 2011 90-day mortal-
ity (also unad-
justed estimates
provided for 14-
day and 30-day)
62/107 (57.9) 37/138 (26.8) OR 3.76 (95%
CI 2.19 to 6.44)
aOR 2.20 (95%
CI 1.03 to 4.71)
Age, disease
severity (SOFA),
MV, lymphocyte
count, propen-
sity score)
Li 2012 Mortality 6/27 (22.2) 1/19 (5.2) OR 5.14 (95%
CI 0.56 to 46.
82)
Not reported N/A
Liem 2009 In-hospital mor-
tality
17/29 (58.6) 9/36 (25.0) OR 4.25 (95%
CI 1.48 to 12.
22)
aOR 4.11 (95%
CI 1.14 to 14.
83)
Neutrope-
nia as surrogate
for severity
Linko 2011 In-hospital mor-
tality
8/72 (11.1) 2/60 (3.3) OR 3.63 (95%
CI 0.74 to 17.
77)
aOR 3.3 (95%
CI 0.5 to 23.4)
Disease severity
(SAPS2)
Mady 2012 In-hospital mor-
tality
20/43(46.5) 10/43 (23.2) OR of 2.87
(95% CI 1.14 to
7.25)
Not reported N/A
Patel 2013 Mortality 11/39 (28.2) 3/24 (12.5) OR 2.75 (95%
CI 0.68 to 11.1)
Not reported -
Sertogullarin-
dan
2011
Mortality 3/11 (27.3) 6/9 (66.7) OR 0.19 (95%
CI 0.03 to 1.28)
Not reported N/A
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Table 3. Summary of studies reporting mortality (Continued)
Viasus 2011 Mortal-
ity (primary out-
come was ’se-
vere disease’ =
ICU admission/
death)
3/37 (8.1) 4/129 (3.1) OR 2.76 (95%
CI 0.59 to 12.
92)
Not reported N/A
Xi 2010 In-hospital mor-
tality
17/52 (32.7) 10/103 (9.7) OR 4.52 (95%
CI 1.89 to 10.
81)
aOR 3.67 (95%
CI 0.99 to 13.
64)
Ethnicity, co-
morbid ill-
ness, symptoms
at onset, labora-
tory tests
aHR: adjusted HR
aOR: adjusted OR
APACHE: Acute Physiology and Chronic Health Evaluation ventilation
CI: confidence interval
CS: corticosteroid
HR: hazard ratio
ICU: intensive care unit
MV: mechanical
OR: odds ratio
RR: risk ratio
SAPS: Simplified Acute Physiology Score
Table 4. Summary of studies reporting relevant outcomes other than mortality
Outcome Study Group treated with cor-
ticosteroids
Group not treated with
corticosteroids
Unadjusted estimate of
effect
Critical disease Han 2011 Early CS
12/17 (70.6)
Late or no CS
26/66 (39.4)
RR 1.8, 95% CI 1.2 to 2.
8†
Composite outcome of
ICU admission/death
Jain 2009 29/86 (33.7) 27/153 (17.6) OR 2.37, 95% CI 1.29 to
4.37
Rate of MV Kim 2011 91/107 (85.0) 71/138 (51.4) OR 5.37, 95% CI 2.87 to
10.05
Rate of MV Linko 2011 53/72 (73.6) 14/60 (23.3) OR 9.17, 95% CI 4.14 to
20.30
Length of ICU stay:
median days (IQR)
Brun-Buisson 2011 22 (13 to 39) 17 (11 to 30) P value = 0.11
LOS: mean days (SD) Kim 2011 30.8 (36.9) 18.9 (20.0) P value < 0.001
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Table 4. Summary of studies reporting relevant outcomes other than mortality (Continued)
LOS
median days (IQR)
Kudo 2012 8.2 (5 to 14) 7.7 (3 to 14) P value = 0.607
LOS: median days
(IQR)
Linko 2011 20 (12 to 34) 8 (5 to 13) P value < 0.001
aRR: adjusted risk ratio
CI: confidence interval
CS: corticosteroid
ICU: intensive care unit
LOS: length of stay
MV: mechanical ventilation
OR: odds ratio
RR: risk ratio
† adjusted risk ratio 1.8, 95% CI 1.2 to 2.8 (following adjustment for co-morbid illnesses, age, pregnancy and obesity).
Table 5. Summary of studies reporting corticosteroid-related adverse events or nosocomial infection
Adverse effect Study Group treated with cor-
ticosteroids
Group not treated with
corticosteroids
Unadjusted estimate of
effect
ICU-acquired
infection
Brun-Buisson 2011 38/83 (45.8) 44/125 (35.2) OR 1.55, 95% CI 0.88 to
2.74
Hospital-acquired in-
fection
Kim 2011 54/107 (50.5) 24/138 (17.4) OR 4.84, 95% CI 2.71 to
8.65
Hospital-acquired in-
fection
Viasus 2011 6/37 (16.2) 4/129 (3.1) OR 6.05, 95% CI 1.61 to
22.75
ICU: intensive care unit
OR: odds ratio
Table 6. Summary of studies reporting outcomes stratified according to different corticosteroid regimens
Subgroup analysis Study Outcome Comments
Early and late CS therapy
compared with no CS therapy
Brun-Buisson 2011 Hospital mortality
Early CS: HR 3.42, 95% CI 1.73 to
6.75; P value = 0.001
Late CS: HR 1.93, 95% CI, 0.84 to
4.43; P value = 0.12
Early treatment defined as ’within 3
days of mechanical ventilation’
Propensity score adjusted analysis
Early CS therapy versus late/
no CS therapy groups com-
bined
Han 2011 Critical illness
RR 1.8, 95% CI 1.2 to 2.8
Early treatment defined as < 72 hours
from influenza-like illness
Multivariate analysis following ad-
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Table 6. Summary of studies reporting outcomes stratified according to different corticosteroid regimens (Continued)
justment for underlying co-morbid
illnesses, age, pregnancy and obesity
Low-dose versus high-dose
CS therapy
Xi 2010 In-hospital mortality
9/30 versus 8/22, P value = 0.854
Low-dose CS therapy defined as ≤
80 mg methylprednisolone or equiv-
alent daily dose
Unadjusted outcome
CI: confidence interval
CS: corticosteroid
HR: hazard ratio
RR: risk ratio
A P P E N D I C E S
Appendix 1. EMBASE (Elsevier) search strategy
#42 #18 AND #41
#41 #26 OR #40
#40 #27 OR #28 OR #29 #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39
#39 (’cross sectional’ NEXT/1 (study OR studies)):ab,ti
#38 (epidemiologic* NEXT/1 (study OR studies)):ab,ti
#37 (observational NEXT/1 (study OR studies)):ab,ti
#36 (’follow up’ NEXT/1 (study OR studies)):ab,ti
#35 (’case control’ NEXT/1 (study OR studies)):ab,ti
#34 (cohort NEXT/1 (study OR studies)):ab,ti
#33 ’cohort analysis’/de
#32 ’prospective study’/de
#31 ’retrospective study’/de
#30 ’longitudinal study’/de
#29 ’family study’/de
#28 ’case control study’/de
#27 ’clinical study’/de
#26 #21 NOT #25
#25 #22 NOT #24
#24 #22 AND #23
#23 ’human’/de
#22 ’animal’/de OR ’nonhuman’/de OR ’animal experiment’/de
#21 #19 OR #20
#20 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR allocat*:ab,ti OR trial:ti OR (doubl* NEXT/1
blind*):ab,ti
#19 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#18 #5 AND #17
#17 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
#16 hydrocortisone*:ab,ti OR prednisolone*:ab,ti OR prednisone*:ab,ti OR dexamethasone*:ab,ti OR methylprednisolone*:ab,ti
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#15 steroid*:ab,ti
#14 ’steroid’/exp
#13 hydroxycorticosteroid*:ab,ti
#12 glucocorticoid*:ab,ti
#11 corticoid*:ab,ti
#10 adrenocorticoid*:ab,ti
#9 adrenocorticosteroid*:ab,ti
#8 (adren* NEAR/2 (hormon* OR steroid*)):ab,ti
#7 corticosteroid*:ab,ti
#6 ’corticosteroid’/exp
#5 #1 OR #2 OR #3 OR #4
#4 h1n1:ab,ti OR h5n1:ab,ti OR h3n2:ab,ti
#3 influenza*:ab,ti OR flu:ab,ti
#2 ’influenza virus a’/exp OR ’influenza virus b’/de
#1 ’influenza’/exp
Appendix 2. CINAHL (Ebsco) search strategy
S17 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16
S16 TI (hydrocortisone* or prednisolone* or prednisone* or dexamethasone* or methylprednisolone*) OR AB (hydrocortisone* or
prednisolone* or prednisone* or dexamethasone* or methylprednisolone*)
S15 TI steroid* OR AB steroid*
S14 (MH “Steroids+”)
S13 TI hydroxycorticosteroid* OR AB hydroxycorticosteroid*
S12 TI glucocorticoid* OR AB glucocorticoid*
S11 TI corticoid* OR AB corticoid*
S10 TI adrenocortic* OR AB adrenocortic*
S9 TI (adren* N2 (hormone* or steroid*)) OR AB (adren* N2 (hormone* or steroid*))
S8 TI corticosteroid* OR AB corticosteroid*
S7 (MH “Adrenal Cortex Hormones+”)
S6 S1 OR S2 OR S3 OR S4 OR S5
S5 TI (h1n1 or h5n1 or h3n2 ) OR AB ( h1n1 or h5n1 or h3n2)
S4 TI (influenza* or flu) OR AB ( influenza* or flu)
S3 (MH “Influenza B Virus”)
S2 (MH “Influenzavirus A+”)
S1 (MH “Influenza+”)
Appendix 3. LILACS (BIREME) search strategy
(mh:“Influenza, Human”OR influenza$ORfluOR grippeORor gripeORmh:“Influenzavirus A”ORmh:b04.820.545.405$ ORmh:
b04.909.777.545.405$ OR mh:“Influenzavirus B” OR mh:b04.820.545.407$ OR mh:b04.909.777.545.407$ OR h1n1 OR h5n1
OR h3n2) AND (mh:“Adrenal Cortex Hormones” OR mh:d06.472.040$ OR corticoesteroides OR corticosteróides OR corticoid$
OR corticosteroid$ OR “adrenal cortex hormone” OR “adrenal cortex hormones” OR adrenocorticosteroid$ OR glucocorticoid$
OR hydroxycorticosteroid$ OR mh:glucocorticoids OR glucocorticóides OR mh:steroids OR esteróides OR mh:d04.808$ OR hy-
drocortison$ OR hidrocortisona OR mh:prednisolone OR prednisolone OR prednisolona OR mh:prednisone OR prednisone OR
prednisona OR mh:dexamethasone OR dexamethasone OR dexametasona OR mh:methylprednisolone OR methylprednisolone OR
metilprednisolona) AND db:(“LILACS”) AND type˙of˙study:(“clinical˙trials” OR “case˙control” OR “cohort” OR “overview” OR
“systematic˙reviews”)
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Appendix 4. Web of Science (Thomson Reuters) search strategy
# 5 361 #4 AND #1
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan = All Years
# 4 2,897,717 #3 OR #2
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan = All Years
# 3 1,700,524 Topic=((case NEAR/1 control) or cohort or “follow up” or observational or longitudinal or retrospective or
prospective or cross-section* or “cross sectional”)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan = All Years
# 2 1,425,723 Topic=(random* or placebo* or crossover* or “cross over” or allocat* or ((doubl* or singl*) NEAR/1 (blind* or
mask*))) OR Title=(trial)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan = All Years
# 1 1,082 Topic=(influenza* or flu or h1n1 or h5n1 or h3n2) ANDTopic=(“adrenal cortex hormone*” or corticosteroid* or
adrenocorticosteroid* or adrenocorticoid* or corticoid* or glucocorticoid* or hydroxycorticosteroid* or steroid*
or hydrocortisone* or prednisolone* or prednisone* or dexamethasone* or methylprednisolone*)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan = All Years
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Research for a clinical trial in pandemic influenza.
Jonathan Nguyen-Van-Tam: The University of Nottingham Health Protection Research Group is currently in receipt of research funds
from GlaxoSmithKline. The group has an unrestricted educational grant for influenza research from F. Hoffmann-La Roche. Research
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on influenza funded by an unrestricted educational grant from Astra Zeneca has also been completed. The aforementioned funding
received fromGSK, F. Hoffmann-La Roche and Astra Zeneca did not support any aspect of this work. JSN-V-T has received funding to
attend influenza-related meetings, lecture and consultancy fees, and research funding from several influenza antiviral drug and vaccine
manufacturers. All forms of personal remuneration ceased in September 2010, but departmental funding for influenza-related research
from GlaxoSmithKline and F. Hoffmann-La Roche remains current. He is a former employee of SmithKline Beecham plc. (now
GlaxoSmithKline), Roche Products Ltd and Aventis-Pasteur MSD (now Sanofi-Pasteur MSD), all prior to 2005, with no outstanding
pecuniary interests by way of shareholdings, share options or accrued pension rights.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We updated the Objectives of this review to add “taking into account differences in timing and doses of corticosteroids”.
We amended the Types of studies to state “We excluded studies with case-control designs due to the inability to determine temporal
effects of corticosteroids on the development of non-mortality outcomes. We excluded studies with fewer than 10 participants.”
We used the Newcastle-Ottawa Scale to assess the risk of bias in studies instead of the Cochrane ’Risk of bias’ tool as all identified studies
were observational. Stratification by 30-day mortality was not possible as stated in the protocol due to the heterogeneity across studies
when reporting mortality. All the studies were conducted at least in part in a hospital setting, and stratification of outcomes according
to in-/out-patient setting was not possible. Subgroup analyses according to corticosteroid regimens and age of study participants could
not be performed due to an insufficient number of studies reporting outcomes stratified according to these variables.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [adverse effects; ∗therapeutic use]; Chemotherapy, Adjuvant [adverse effects]; Cross Infection [etiology];
Influenza A Virus, H1N1 Subtype; Influenza, Human [∗drug therapy; mortality]; Intensive Care Units [statistics & numerical data];
Observational Studies as Topic
MeSH check words
Humans
51Corticosteroids as adjunctive therapy in the treatment of influenza (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
